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Introduction
1.1 CeRviCAL CAnCeR
Cervical cancer is one of the most common female malignancies worldwide. In the 
United States, the yearly incidence exceeds 12000 and more than 4000 women die as a 
result of this disease (1). In the Netherlands, per year, on average around 700 women are 
diagnosed with cervical cancer. For 224 of those women the disease is fatal (2).
Cervical cancer mainly spreads by tumor invasion in surrounding organs and via 
lymph nodes to other parts of the body. The para-aortic lymph nodes are secondary 
stations and are always paralleled with metastases in the pelvic lymph nodes. At the 
time of diagnosis, the most important prognostic factors are tumor size, local extent 
and spread to the lymph nodes. A higher stage of disease means a lower overall 5-year 
survival with a worst case scenario for survival lower than 20% (2).
Early detection through population screening programs, starting at the age of 30 years 
in the Netherlands, has a beneficial impact on the incidence of cervical cancer (2). The 
most important risk factor for cervical cancer is a persistent infection with an oncogene 
Human Papilloma Virus type (3). Risk factors for HPV persistence and development of 
cervical cancer are sexual intercourse at a young age, multiple sexual partners, smoking, 
and immune suppression (3).
The standard treatment for cervical cancer depends on the FIGO-stage (4). In low stage 
disease (tumors only localized in the cervix or with minimal spread to the proximal va-
gina), surgery is the first choice of treatment. In higher stages, locally advanced disease 
is treated with either chemo-radiation or with neoadjuvant chemotherapy followed by 
radiotherapy and hyperthermia. In case of metastatic disease (stage IVB), patients are 
treated in a palliative setting with chemotherapy.
1.2 RADioTHeRAPy
Radiotherapy is a treatment modality that uses ionizing radiation to eradicate tumor 
cells. An important pathway leading to cell kill is induction of lethal damage in the cell 
DNA.
In case radiotherapy is applied for cervical cancer, the tumor is both irradiated with X-
ray beams that are directed from outside the patient towards the tumor (external beam 
radiotherapy, EBRT), and with a radioactive source that is temporarily placed inside the 
body in order to locally deliver a high dose to the tumor (Brachytherapy). Total treatment 
time is usually 5-7 weeks, including chemotherapy or hyperthermia (above).
In EBRT, Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated 
Arc Therapy (VMAT) are modern delivery techniques, used to increase organ at risk 
(OAR) sparing with more conformal dose distributions than conventional 3D conformal 
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radiotherapy (3DCRT) (5-8). However, in treatment of cervical cancer, large and complex 
geometrical day-to-day variations in the pelvic area limit the potential positive impact 
of IMRT and VMAT (9-12). Especially bladder filling variations have a large impact on the 
daily position of the fundus of the cervix-uterus in the body, and are correlated with 
motion in AP direction (13). Earlier research (10,11) showed that due to large anatomical 
variations, the cervix-uterus was underdosed when IMRT was given with a Clinical Target 
Volume (CTV) to Planning Target Volume (PTV) margin of 15 mm. Another analysis dem-
onstrated that a pre-treatment established motion model, correlating bladder volume 
with cervix-uterus position and shape, could be used to predict the position of the 
cervix-uterus during treatment (5,14). Bondar et al. (15) showed that the pre-treatment 
cervix-uterus motion model could be used to make plan libraries containing treatment 
plans for several Internal Target Volumes (ITV), each linked to a different bladder volume 
range.
Since September 2011, the EBRT part of the treatment of advanced cervical cancer 
patients in our department is performed using an online adaptive Plan-of-the-Day 
protocol. The goal of the protocol is to irradiate the patients with patient-specific, 
relatively small CTV-to-PTV margins. The protocol is based on a patient-specific plan 
library. For each library plan, the cervix-uterus is covered with a high dose for a specific 
range of possible cervix-uterus positions and shapes (above). Together, these plans with 
relatively small PTV margins should cover the full motion range of the cervix-uterus. On 
top of these plans, a library always contains a motion-robust back-up plan with gener-
ous margins. Each treatment fraction, prior to dose delivery, an in-room Cone Beam CT 
(CBCT) scan is made of the patient on the treatment couch. This CBCT is used to select 
the plan that best fits the anatomy-of-the-day from the plan library. In case none of the 
small margin plans fit with the anatomy-of-the-day, or in case of bad image quality, the 
motion-robust backup plan is chosen for treatment.
1.3 THiS THeSiS
In this thesis, we have investigated and further improved the Plan-of-the-Day approach 
for locally advanced cervical cancer patients.
In Chapter 2 we report on the clinical introduction of the first two phases of our online 
Plan-of-the-Day protocol, including in total 64 patients. In the first phase, a patient’s 
treatment library consisted of two plans, an IMRT plan with an individualized CTV-to-
PTV margin, and a motion-robust 3DCRT plan. In the second phase, patients with large 
cervix-uterus motion as a function of bladder filling (assessed in the treatment planning 
phase) had a library consisting of two IMRT plans (empty-to-half-full and half-full-to-full 
bladder plans) with relatively small margins, and the 3DCRT backup plan.
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With the introduction of IMRT and adaptive approaches using smaller CTV-to-PTV 
margins, EBRT for cervical cancer has become more sensitive to intra-fraction uncer-
tainties. In Chapter 3, we systematically investigated the intra-fraction motion of the 
cervix-uterus, assessed with pre- and post-fraction CBCT scans. Further, we evaluated to 
what extent changes in bladder or rectum filling during treatment had an impact on the 
intra-fraction cervix-uterus motion.
Almost all our cervical cancer patients were treated in prone position using a bel-
lyboard for small bowel displacement. This setup was based on an internal study, per-
formed prior to introduction of the online adaptive approach and showing superiority 
in OAR sparing compared to supine treatment (16). However, as there was no adaptive 
treatment, large CTV-to-PTV margins were used in that study. In chapter 4 we performed 
a planning study to compare prone and supine treatment for small margin adaptive 
radiotherapy. Small bowel sparing was the most important parameter in this study.
In Chapter 5, we prospectively investigated the Quality of Life (QoL) of our cervical 
cancer patients during the radiation treatment phase with the Plan-of-the-Day ap-
proach, using validated EORTC questionnaires (QLQ-C30 and CX-24), thereby covering 
dynamics of the acute treatment phase.
In Chapter 6, the optimal number of library plans in adaptive radiotherapy for locally 
advanced cervical cancer was investigated by a dosimetric evaluation.
Chapter 7 contains a general discussion on the work presented in the previous chap-
ters, including suggestions for future research.
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AbSTRACT
Purpose
To evaluate the clinical implementation of an online adaptive Plan-of-the-Day protocol 
for nonrigid target motion management in locally advanced cervical cancer intensity 
modulated radiation therapy (IMRT).
Material & Methods
Each of the 64 patients had four markers implanted in the vaginal fornix to verify the posi-
tion of the cervix during treatment. Full and empty bladder computed tomography (CT) 
scans were acquired pre-treatment to build a bladder volume dependent cervix-uterus 
motion model for establishment of the plan library. In the first phase of clinical imple-
mentation, the library consisted of one IMRT plan based on a single model-predicted in-
ternal target volume (mpITV), covering the target for the whole pre-treatment observed 
bladder volume range, and a 3D conformal radiation therapy (3DCRT) motion-robust 
backup plan based on the same mpITV. The planning target volume (PTV) combined the 
ITV and nodal clinical target volume (CTV), expanded with a 1-cm margin. In the second 
phase, for patients showing >2.5-cm bladder-induced cervix-uterus motion during 
planning, two IMRT plans were constructed, based on mpITVs for empty-to-half-full and 
half-full-to-full bladder. In both phases, a daily cone beam CT (CBCT) scan was acquired 
to first position the patient based on bony anatomy and nodal targets, and then select 
the appropriate plan. Daily post-treatment CBCT was used to verify plan selection.
Results
Twenty-four and 40 patients were included in the first and second phase, respectively. 
In the second phase, 11 patients had two IMRT plans. Overall, an IMRT plan was used in 
82.4% of fractions. The main reasons for selecting the motion-robust backup plan were, 
uterus outside the PTV (27.5%), and markers outside their margin (21.3%). In patients 
with two IMRT plans, the half-full-to-full bladder plan was selected on average in 45% of 
the first 12 fractions, which was reduced to 35% in the last treatment fractions.
Conclusion
The implemented online adaptive Plan-of-the-Day protocol for locally advanced cervi-
cal cancer enables (almost) daily tissue-sparing IMRT.
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2.1 inTRoDuCTion
Large and complex day-to-day tissue variations in the pelvic area limit the efficacy 
of intensity modulated radiation therapy (IMRT) for locally advanced cervical cancer 
(5,15,17,18). Bladder-filling variations can have large impact on shape and position of 
the cervix-uterus. Drinking instructions, used to minimize bladder-filling variations, has 
limited efficacy (10). Previously, a dosimetric study demonstrated that in 6 of 14 patients, 
the cervix-uterus was underdosed when applying IMRT with a clinically recommended 
clinical target volume (CTV)-to-planning target volume (PTV) margin of 15 mm (9,11). 
To guarantee adequate coverage for a large proportion of patients, generous margins 
of 24-40 mm are required (12,14,15). However, those generous margins jeopardize 
tissue-sparing properties of IMRT. In proof-of-principle analyses, it was shown that a pre-
treatment established motion model could be used to predict the position of the cervix 
and uterus during treatment (5,14). This concept was elaborated in a study by Bondar 
et al. (15), which showed that a personalized PTV, based on a pre-treatment acquired 
shape model improved normal tissue sparing. Furthermore, they demonstrated that 
the shape model could be used to make a plan library containing treatment plans that 
are linked to a certain bladder volume range. Based on these results, we developed a 
novel online adaptive protocol using daily cone beam computed tomography (CBCT) 
based plan selections from a plan library that explicitly accounted for patient-specific 
bladder volume-dependent cervix-uterus shape and position variations. This protocol is 
currently evaluated in a prospective clinical implementation. In this report, we describe 
the practical implementation of the protocol and report our experience with the first 
64 patients. To our knowledge, this is the first report describing clinical experience with 
such a Plan-of-the-Day (PotD) approach for cervical cancer.
2.2 MATeRiAL AnD MeTHoDS
Patients
In our institute, patients with an intact uterus receiving definite radiation therapy have 
been included in the PotD protocol since June 2011. Patients with positive para-aortic 
lymph nodes were not eligible. This study reports on the first 64 patients treated with 
this protocol. Routine pre-treatment work-up consisted of gynecologic examination 
under anesthesia and computed tomography (CT) scans of thorax and abdomen. Dur-
ing the examination under anesthesia, four polymer-based markers (PolyMark; Cortex 
Manufacturing Inc, Lake Stevens, WA) were implanted in the submucosa of the vaginal 
fornix to verify the position of the cervix during treatment. Patients with International 
Federation of Gynecology and Obstetrics (FIGO) cancer stages up to IIB medial were 
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treated with chemoradiation, and those with FIGO stage IIB lateral or higher were 
treated with concurrent radiation therapy and hyperthermia (4).
Fifty-seven patients were treated in prone position, using a belly board. For maximum 
sparing of organs at risk (OAR), daily treatment with a filled bladder was pursued by 
instructing patients to drink 300 ml of water two hours prior to treatment, to empty 
the bladder and drink an additional 300 ml of water one hour prior to treatment. Daily 
CBCT-based plan selection from an individualized plan library was applied to account 
for (large) residual interfraction bladder filling variations and the patient-specific impact 
of such variations. As detailed below, in the first phase of implementation, plan librar-
ies contained a single IMRT plan plus a motion-robust 3D conformal radiation therapy 
(3DCRT) plan (backup plan). In the second phase, plan libraries for patients with large 
bladder-induced cervix-uterus motion consisted of two IMRT plans (for relatively empty 
and full bladders, respectively) and the backup plan. The dose prescribed to the PTV was 
46 Gy in 23 daily fractions. All patients received 21 Gy in three brachytherapy sessions.
Establishment of patient-specific, model-predicted Internal Target Volumes
To model each individual patient bladder filling and subsequent impact on cervix-
uterus motion, a full and an empty bladder CT scan was acquired pre-treatment with 
the patient in the treatment position. To obtain a sufficiently filled bladder, the same 
drinking protocol as that used for treatment was used (patient section). After acquisition 
of the full bladder CT scan, patients were asked to empty their bladder, followed directly 
by a second CT scan acquisition.
The two scans were aligned on the bony anatomy. In both scans, the bladder and 
the cervix-uterus CTV, consisting of uterus, cervix, and superior part of the vagina, were 
manually delineated. An in-house, nonrigid registration algorithm was then used to 
derive a patient-specific cervix-uterus shape model, defining for every possible blad-
der volume the corresponding 3D cervix-uterus structure (19). With this shape model, 
model-predicted internal target volumes (mpITVs) were generated for PTV construction 
and planning. In the first phase, a single mpITV, containing the cervix-uterus model 
shapes for all intermediate bladder volumes, was used for plan library generation. This 
mpITV was extended if the bladder in the full-bladder scan was not sufficiently full 
(<700ml) or empty in the empty-bladder scan (>50ml), according to the extension rule 
defined by Bondar et al. (15). Compared to the common use of a large population-based 
margin, PTV establishment based on this whole-bladder-volume range mpITV improved 
healthy tissue sparing for patients with small cervix-uterus motion. For patients with 
large cervix-uterus motion, this mpITV approach guarantees adequate CTV coverage 
at the cost of large volumes of healthy tissue irradiated to a high dose. Therefore, in 
the second phase, for patients with a cervix-uterus motion >2.5 cm (measured at the 
fundus of the uterus), 2 extra mpITVs were used for plan generation, 1 containing all 
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cervix-uterus model shapes for empty-to-half-full bladders and the other the shapes for 
half-full-to-full bladders. Figure 1 shows mpITVs on a full bladder CT scan for 2 second-
phase patients.
Plan library generation using mpITVs
The full-bladder CT scan, in which the nodal CTV, parametria, and OARs were contoured, 
was always used for treatment planning. To construct PTVs, generated mpITVs were 
combined with the nodal CTV and parametria and were expanded with a 1-cm margin 
to account for intrafractional errors and model imperfections. In the first phase, the 
plan library contained one IMRT plan, generated for the PTV derived from the whole-
bladder-volume range mpITV. In the second phase, the library contained IMRT plans 
for the empty-to-half-full and half-full-to-full mpITVs. High quality IMRT plans were 
generated in a two-step procedure. First, Erasmus-iCycle, an in-house algorithm for 
fully automated multi-criteria plan generation, was used to automatically generate a 
7- to 9-beam IMRT plan with optimized beam orientations and fluence profiles (20). To 
establish a clinical, segmented IMRT plan, an individual template with optimized beam 
angles and achieved plan parameters was imported into our clinical treatment planning 
system (Monaco; Elekta AB Stockholm, Sweden) (21). For all patients, the plan library was 
completed with a 3D-conformal, four-field box plan generated using the XIO planning 
system (Elekta AB). In both phases, the PTV for this plan was always based on the whole-
bladder-volume range mpITV. Due to the large PTV and the 3D box shape of the dose 
distribution, 3DCRT plans were robust against uncertainties in cervix-uterus position.
a
Figure 1. a) Sagittal view of the full bladder CT scan with the corresponding cervix-uterus (yellow), 
cervix-uterus of the empty-bladder CT (red), and whole-bladder range mpITV (white) of a patient 
with small cervix-uterus motion. b) Sagittal view of the full bladder CT for a patient with large cervix-
uterus motion. Black dashed line denotes the empty-to-half-full mpITV, and the white dashed line 
denotes the half-full-to-full mpITV.  
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Figure 1. (a) Sagittal view of the full bladder CT scan with the corresponding cervix-uterus (yellow), cer-
vix-uterus of the empty-bladder CT (red), and whole-bladder range mpITV (white) of a patient with small 
cervix-uterus motion. (b) Sagittal view of the full bladder CT for a patient with large cervix-uterus motion. 
Black dashed line denotes the empty-to-half-full mpITV, and the white dashed line denotes the half-full-
to-full mpITV.
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Preparations for online plan selection
To facilitate plan selection, the following structures were made available in the software 
application used to acquire and register CBCT scans (XVI version 4.5.1b141; Elekta AB). 
For treatments with one IMRT plan, the PTV and marker tubes were imported. These 
marker tubes were created by connecting, pair-wise, the implanted markers in the 
aligned (patient section) empty and full bladder CT scans by a line, which was expanded 
with a 1-cm margin. When the library consisted of 2 IMRT plans, 2 tubes per marker 
pair (1 for the empty-to-half-full and 1 for the half-full-to-full plan) were imported by 
splitting each connecting line into 2 equal parts followed by the 1-cm margin expan-
sion. The marker tubes were used to verify the position of implanted markers during 
daily plan selection (daily image-guidance section). For patients with 2 MRT plans, the 
marker tubes, 2 PTVs, and a constructed half-full bladder structure were imported to 
select between the 2 IMRT plans.
Daily image guidance and plan selection procedures
CBCT scans were acquired daily before dose delivery and registered to the planning CT 
scan, using intensity-based registration in XVI software. Required translational patient 
displacements were automatically executed by a remote couch translation (TheraView 
couch setup assistant; Cablon Medical, Leusden, The Netherlands). In addition, when 
a pelvis rotation of more than 4° around the left-right axis was observed, nodal CTV 
coverage was verified offline. If the nodal CTV was underdosed, the field was enlarged in 
the anterior-posterior direction at the cranial border. For patients with two IMRT plans, 
a second CBCT scan was acquired after dose delivery to verify intrafraction anatomy 
stability.
During the first phase, the decision was carried out semi-online. In a multidisciplinary 
team, it was decided to use the motion-robust backup plan for treatment and to disable 
the IMRT plan for the remainder of the fractions. In this phase only one IMRT plan was 
available. During the second phase, two IMRT plans were available for each fraction and 
plan selection and verification was performed online. A decision tree was used to guide 
the daily plan selection process. For patients with two IMRT plans, it was first determined 
whether the bladder was more or less than half-full using the half-full bladder structure 
displayed in the matched CBCT scan. This step was skipped for patients with one IMRT 
plan. Subsequently, the PTV and marker tubes of the chosen IMRT plan were shown in 
the matched CBCT scan. Then, it was verified that at least three markers were inside the 
marker tubes and the uterus was inside the PTV (Fig 2). If both conditions were fulfilled, 
the IMRT plan was selected; otherwise, the backup plan was used. In that case, for extra 
safety, the 95% isodose line in the backup plan was inspected to ensure target coverage. 
Details for how plan selection was carried out in the record and verify system (MOSAIQ 
version 2.3; Elekta AB), can be found in Appendix 2A.
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evaluation of the online adaptive Plan-of-the-Day protocol
For all patients, daily plan choices were recorded. In case the backup plan was selected, 
the reason was recorded as well. Times needed for the various steps of the plan selec-
tion procedure were assessed (phase two only). For patients with two IMRT plans, the 
robustness of the plan choice relative to intra-fraction anatomy changes was verified 
with a post-fraction CBCT scan. For all patients with two IMRT plans and a representative 
case with small cervix-uterus motion, we compared IMRT dose-volume-histogram (DVH) 
parameters with those of the backup plan (see Appendix 2B).
2.3 ReSuLTS
Twenty-four patients were included in the first phase (only one IMRT plan in the library, 
independent of cervix-uterus motion induced by bladder volume changes). In the sec-
ond phase, 29 patients had a single IMRT plan in the plan library, whereas for 11 patients 
with large cervix-uterus motion, the library contained two IMRT plans.
During the first phase, 17 of 24 patients received IMRT in all 23 fractions. For all 24 
patients in 84.3% of the treatment fractions, the IMRT plan was delivered. Figure 3 
shows a continuous increase in the use of the backup plan, except for fraction 9: for two 
patients, the IMRT plan was available only from fractions 3 and 8 for logistic reasons. 
During the second phase 11 of 29 patients with one IMRT plan received IMRT for all 23 
fractions (Fig. 4a). On average, in 81.1% of the treatment fractions, IMRT was selected. 
For patients with two IMRT plans, IMRT was selected in 81.8% of the fractions (Fig. 4b). 
Figure 2. Sagittal view (left) of a CBCT scan made in the second implementation phase for plan 
selection. The yellow contour represents the cervix-uterus. The PTV for the half-full-to-full bladder 
plan is projected in black, and the white solid line denotes the reconstructed half-full bladder. The 
purple contours are the marker tubes. For this fraction, the PTV covers the uterus completely. The 
transversal slice (right) shows that the two markers in this slice are inside their tube.  
 
 
 
 
Figure 2. Sagittal view (left) of a CBCT scan made in the second implementation phase for plan selection. 
The yellow contour represents the cervix-uterus. The PTV for the half-full-to-full bladder plan is projected 
in black, and the white solid line denotes the reconstructed half-full bladder. The purple contours are the 
marker tubes. For this fraction, the PTV covers the uterus completely. The transversal slice (right) shows that 
the two markers in this slice are inside their tube.
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Figure 4b illustrates the fact that the half-full-to-full bladder plan was mostly selected 
during the first half of the treatment (45%, compared to 35% for the second half ). The 
empty-to-half-full bladder plan was selected in 51.2% during the second treatment half. 
For two patients, target coverage of the backup plan was still insufficient and the backup 
plan was adapted for subsequent fractions. For 4 fractions in 3 patients, rapid filling of 
the bladder as detected in the post-treatment CBCT scan would have led to selecting 
the half-full-to-full-bladder plan instead of the selected empty-to-half-full-bladder plan. 
For one fraction in one patient, urinary incontinence led to an emptier bladder at the 
fraction end. Projection of the delivered dose onto the post-fraction CBCT scan showed 
that the 1-cm margin was adequate to ensure coverage by 95% of the prescription dose 
in all these cases.
The potential OAR sparing was evaluated for all patients with two IMRT plans. The 
bowel cavity volume receiving 99% of the prescription dose was 127 cc on average for 
half-full-to-full IMRT compared with 172 cc for the backup plan, a reduction of 26% 
(range 2-79%). Similarly, for the empty-to-half-full IMRT plan the volume was 210 cc 
compared with 296 cc for the backup plan evaluated on the empty-bladder CT scan 
(reduction of 29%; range 9-89%). For further results, we refer to Appendix 2B.
The backup plan was selected in 17.5% of all fractions. The main reasons for selecting 
this plan was that the uterus was outside the PTV (27.5%), markers were outside their 
1-cm margin (21.3%) or both (21.7%), insufficient CBCT scan quality (10.5%), pelvic rota-
tions (5.8%), and other problems (13.2%). Visual inspection suggests that uterus outside 
the PTV and/or markers outside their tubes was mainly caused by differences in rectum 
filling compared to the planning CT scan.
 
Figure 3. Selected plans across the treatment course for patients with one IMRT plan in the first 
phase. If the motion-robust backup plan was chosen once, this was continued for all fractions. For 
logistic reasons, IMRT plan was only available from fractions three and 8 for 2 patients, which 
explains the increase in selected IMRT plans at the ninth fraction.  
 
 
 
Figure 3. Selected plans across the treatment course for patients with one IMRT plan in the first phase. If 
the motion-robust backup plan was chosen once, this was continued for all fractions. For logistic reasons, 
IMRT plan was only available from fractions three and 8 for 2 patients, which explains the increase in se-
lected IMRT plans at the ninth fraction.
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Treatment delivery times
Patient setup and CBCT acquisition took on average 5.0 and 2.4 minutes, respectively. 
In the second phase, plan selection for patients with a single or two IMRT plans took 2.2 
and 2.4 minutes. The mean delivery time for IMRT was 11.3 minutes, whereas 3DCRT 
dose delivery took only 2.3 minutes.
2.4 DiSCuSSion
In this study, we described and evaluated a two-phase clinical introduction of a novel 
online adaptive PotD strategy for locally advanced cervical cancer. For each fraction, a 
CBCT scan was used for selection of the most appropriate plan from a library containing 
1 or 2 IMRT plans and a motion-robust 3DCRT backup plan. All plans were generated for 
established patient-specific ITVs to effectively individualize planning margins. Results 
a.
Figure 4. (a) Selected plans across the treatment course for patients with one IMRT plan in the 
second phase. Plan selection was carried out online. (b) Selected plans for patients with two IMRT 
plans in the second phase. At the end of treatment, the empty-to-half-full bladder plan was chosen 
more often compared to the half-full-to-full bladder plan at the start of treatment. 
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Figure 4. (a) Selected plans across the treatment course for patients with one IMRT plan in the second 
phase. Plan selection was carried out online. (b) Selected plans for patients with two IMRT plans in the sec-
ond phase. At the end of treatment, the empty-to-half-full bladder plan was chosen more often compared 
to the half-full-to-full bladder plan at the start of treatment.
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show that in most of the treatment fractions, a tissue-sparing IMRT plan could be used 
for treatment.
Online adaptive radiotherapy has been used and investigated previously for bladder 
cancer, but to our knowledge, this is the first report evaluating its clinical use for the 
treatment of locally advanced cervical cancer. Meijer et al reported on the clinical use of 
an online adaptive protocol in bladder cancer (22).
A limitation of the current approach is that the pre-treatment shape model includes 
only one parameter, bladder volume, whereas rectum and tumor regression may also 
impact the shape and position of the CTV (11,17). Furthermore, it assumes a linear 
relationship between bladder filling and cervix-uterus motion (5). Correctness of the 
mpITVs may also be compromised by uncertainties in the pre-treatment determined 
bladder volume range. Therefore, the model was used to expand the mpITV beyond the 
pre-treatment observed bladder volume range (15). Model imperfections were partly 
accounted for by the 1-cm ITV-to-PTV margin. In case these measures rendered insuf-
ficient, the motion-robust backup plan was used.
Further tissue-sparing could potentially be obtained by more densely populating the 
plan library (eg, by subdividing the bladder volume range into three or more subranges). 
Bondar et al (15), however, demonstrated that adding more subranges did not improve 
sparing as it was limited by uncertainties in the pre-treatment-established prediction 
model with bladder volume as the only input parameter. Therefore, future research will 
be focused on expanding the plan library to include rectum-filling variations and on 
updating the library during the treatment to account for tumor regression (23).
Plan selection was based on daily acquired online CBCT scans. The fact that the im-
age quality of these scans is not always sufficient to visualize the relevant structures 
introduces another limitation. To ease plan selection, markers were implanted and 
margins were constructed around these markers for quick verification. Moreover, the 
motion-robust backup plan could be selected in case the image quality was insufficient. 
The latter situation occurred in 1.8% of all fractions. Daily variation in rectum filling occa-
sionally caused the uterus and/or markers to be outside the PTV. In the future, patients 
may benefit from laxation before the acquisition of the planning CT scan and during 
treatment.
A well-trained team is mandatory to safely execute the PotD protocol within reason-
able treatment times. If in doubt, on coverage by IMRT, the policy was to select the 
backup plan. Knowledge of the relevant anatomy and experience in interpreting CBCT 
images with varying image quality is necessary to give the team sufficient confidence 
to select IMRT. A physician (SH) always verified online the plan selection for patients 
with two IMRT plans. The increased planning workload could become an impediment 
for inclusion of more plans in the plan libraries. To avoid this, there is a definite need 
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for automated planning techniques. Recently, Voet et al (21,24) investigated automated 
planning for head and neck and prostate cancer patients.
In this study, we did not include a full dosimetric evaluation of the PotD strategy. In 
a previous publication of Bondar et al (15), the dosimetric benefit of PotD was already 
demonstrated. Part of future research is to delineate all the CBCT scans and accumulate 
the dose nonrigidly. To illustrate the potential benefit, we performed a DVH analysis 
(see Appendix 2B) that demonstrated a consistent benefit of PotD compared with the 
single-plan 3DCRT.
2.5 ConCLuSion
This work demonstrates that a personalized online adaptive radiation therapy strategy 
to manage complex deformable target motion in the treatment of locally advanced 
cervical cancer is feasible and requires limited extra treatment time. To ensure a safe 
introduction of this personalized approach, we recommend the use of a motion-robust 
backup plan to guarantee adequate coverage in all treatment fractions. Future research 
is required to expand the plan library such that more tight-fitting plans can be selected 
and dose to healthy tissues can be further reduced.
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AbSTRACT 
background & purpose
With the introduction of Intensity Modulated Radiotherapy (IMRT) and image-guided 
Plan-of-the-Day strategies, the treatment of cervical cancer has become more sensitive 
to intra-fraction uncertainties. In this study, we quantified intra-fraction changes in 
cervix-uterus shape, bladder and rectum filling, and patient setup using pre- and post-
fraction CBCT scans.
Materials & Methods
A total of 632 CBCT scans were analyzed for 16 patients with large tip-of-uterus displace-
ment (>2.5cm) measured in an empty and full bladder CT scan. In all scans, the blad-
der, cervix-uterus, and rectum were delineated. For rectum and bladder, intra-fraction 
volume changes were assessed. Systematic cervix-uterus intra-fraction displacements 
were obtained by non-rigidly aligning the pre-fraction cervix-uterus to that in the post-
fraction CBCT. Intra-fraction patient setup changes were obtained by rigidly aligning 
pre- and post-CBCTs using the bony anatomy.
Results
The mean time between pre- and post-fraction CBCT scan was 20.8 minutes. The 
group-mean intra-fraction displacements averaged over the cervix-uterus were 
0.1±1.4/1.8±1.5/-2.8±1.8 (LR/CC/AP) mm. The group-mean 5th and 95th percentile 
intra-fraction displacements were -2.3,2.1/-0.8,4.9/-5.8,0.5 (LR/CC/AP) mm. There was a 
significant correlation between bladder inflow rate and cervix-uterus motion (R=0.6 and 
p<0.01). Intra-fraction changes in patient setup were 1.3/0.4/0.6 and 1.4/1.0/1.1 mm (LR/
CC/AP), for systematic and random changes, respectively.
Conclusion
Intra-fraction cervix-uterus motion can be considerable and should be taken into ac-
count using appropriate PTV margins.
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3.1 inTRoDuCTion
Intensity Modulated Radiotherapy (IMRT) is a standard treatment technique for locally 
advanced cervical cancer patients and often combined with brachytherapy, chemother-
apy, or hyperthermia depending on FIGO stage. IMRT improves sparing of healthy tissue 
as opposed to conventional 3-dimensional conformal radiotherapy due to its capacity 
to concavely shape the dose distribution (7,8,12,14). In our institute, IMRT is used in a 
library-based Plan-of-the-Day (PotD) strategy to further improve healthy-tissue sparing 
for patients with large, bladder-filling induced, changes in position and shape of the 
cervix-uterus (15,25). Each fraction, an in-room Cone Beam CT (CBCT) scan is acquired 
just before dose delivery, and the plan in the pre-treatment established plan library that 
best matches the anatomy in the CBCT scan is selected for treatment. Uncertainties from 
intra-fraction bladder or rectum filling or intra-fraction changes in patients’ setup need 
to be accounted for in the Clinical-Target-Volume (CTV) to Planning-Target-Volume (PTV) 
margin of the library plans. As only limited data is available on intra-fraction cervix-uterus 
motion and intra-fraction changes in patient setup (26-28), our clinical PotD practice 
includes daily acquisition of a post-fraction CBCT scan to verify target coverage in the 
presence of the above mentioned intra-fraction uncertainties. The aim of this study is 
to analyze the nature and extent of the intra-fraction motion of the cervix-uterus and 
patient, which can be used to better estimate their contributions to the CTV-to-PTV 
margin. To this end, we analyzed the acquired pre- and post-fraction CBCT scans.
3.2 MATeRiAL AnD MeTHoDS
Patient data
Daily pre- and post-fraction CBCT scans were analyzed for 16 cervical cancer patients 
with a displacement of >2.5 cm of the uterine fundus in a planning CT-scan acquired 
with a full bladder, compared to a planning CT scan acquired with an empty bladder. 
Each patient had two IMRT plans in the library, one covering the tumor for an empty to 
half full bladder range, the other for a half full to a full bladder range. To construct the 
Internal Target Volumes (ITV) for the two IMRT plans, non-rigid registration was used to 
build a patient-specific bladder-volume-dependent motion model from cervix-uterus 
contours in the full and empty bladder planning CT scans (15). To generate the two PTVs, 
the ITVs were combined with the nodal CTV and parametria, and expanded with a 1 cm 
margin. The full-bladder CT scan, in which the CTV (consisting of uterus, cervix and the 
superior part of the vagina), nodal CTV, parametria, and organs at risk were contoured, 
was used for treatment planning. Seven to nine beams were used to create step-and-
shoot IMRT plans. For further details we refer to Heijkoop et al. and Sharfo et al. (25,29). 
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For all patients, the plan library was completed with a 3D conformal, four-field box plan. 
This plan, designated as the backup plan, was robust against uncertainties in the cervix-
uterus shape and position but had poor healthy tissue sparing. For this backup plan the 
full and empty bladder ITV were combined and expanded with 1 cm. Due to the setup of 
the four-field technique we created a box of dose (95% isodose) around the PTV. It was 
selected in case neither of the two IMRT plans fitted the observed anatomy in the pre-
fraction CBCT scan, or in case the CBCT-quality was insufficient for proper plan selection. 
To further maximize organ-at-risk (OAR) sparing, we aimed at daily treatment with a full 
bladder by instructing patients to drink 300 ml of water two hours prior to treatment, to 
empty the bladder one hour prior to treatment and drink an additional 300 ml of water. 
All patients were treated in prone position and received 46 Gy in 23 daily fractions.
Each fraction, the acquired pre-fraction CBCT scan was first used to position the 
patient’s bony anatomy and nodal targets according to the planning CT scan. Next, the 
CBCT scan was used to select a treatment plan from the library. In case an IMRT plan was 
selected (in the majority of fractions), a post-fraction CBCT scan was acquired to verify 
whether the target was still within the PTV in spite of possible intra-fraction motion. For 
this study, the CTV, bladder and rectum were delineated in all pairs of pre- and post-frac-
tion CBCT scans by a clinician (SH), and checked by an experienced radiation-oncologist 
(JM). To maximize consistency of the delineations automatically computed segmenta-
tions were used (30). In this process, for each patient, the first pre-fraction CBCT scan 
was manually delineated after which the contours were automatically propagated to all 
remaining pre-fraction CBCT scans and manually edited. Next, the validated contours 
of each pre-fraction CBCT scan were propagated automatically to the corresponding 
post-fraction CBCT scan and again manually edited.
intra-fraction bladder and rectum filling changes
The volumetric meshes derived from the bladder and rectum contours were used to 
quantify the changes in bladder and rectum filling in ml between the pre- and post-frac-
tion CBCT scan, as well as the inflow rate of the bladder and rectum during a treatment 
fraction. A Pearson correlation coefficient was calculated to determine the correlation 
between inflow rate of the bladder and rectum and intra-fraction cervix-uterus motion 
(see below for how the motion was quantified). Regression analysis was performed to 
relate the bladder inflow rate to the volume of the bladder at the start of a treatment 
fraction. All statistical analyses were performed using SPSS 20.0 and p-values less than 
0.05 were considered statistically significant.
intra-fraction motion of the cervix-uterus
In order to assess the internal organ motion of the cervix-uterus relative to the bony 
anatomy in a treatment fraction, the post-fraction scan was first rigidly registered to 
31
Intra-fraction motion in online adaptive radiotherapy for locally advanced cervical cancer
the pre-fraction scan for all pairs of CBCT scans. Intra-fraction patient setup changes 
were quantified separately (see below). Next, the cervix-uterus surfaces in the pre- and 
post-fraction scans were non-rigidly registered using an in-house developed non-rigid 
registration method (31). The method simultaneously estimates the correspondence 
between points on two surfaces and the transformation. The result of a non-rigid 
registration is an intra-fraction displacement vector for each point on the cervix-uterus 
surface in the pre-fraction CBCT scan. In addition, for each patient, the cervix-uterus in 
the first pre-fraction CBCT was non-rigidly registered to the cervix-uterus shape in all 
remaining 22 pre-fraction CBCT scans. The obtained point correspondences allowed for 
calculation of the patient-specific average cervix-uterus shape over all fractions and for 
collection of the motion statistics from each fraction on this average shape. Next, for 
each patient, the mean intra-fraction displacement in all three directions was calculated 
for each point on the average cervix-uterus shape, where the mean was taken over all 
treatments fractions. The mean displacements quantify the systematic component of 
the intra-fraction motion for each point on the cervix-uterus shape. Then, we calculated 
the mean and the 5th and 95th percentiles of these displacements for each patient. The 
5th and 95th percentiles are the left upper limit and the right lower limit of the 5% tail of 
the displacement distribution on each patient’s average cervix-uterus. These values can 
be used to establish a margin to account for intra-fraction cervix-uterus motion. The 
patients’ mean and the patients’ 5th and 95th percentiles of the systematic intra-fraction 
motion were translated to group statistics by calculating the group-mean and standard 
deviation of these parameters. Positive values for LR, CC and AP pointed at motion in 
right, cranial and anterior directions, respectively. The accuracy of the non-rigid reg-
istration was quantified by the Hausdorff distance of the pre-fraction contours to the 
transformed post-fraction contours. The Hausdorff distance is a measure for the distance 
between two structures. It is defined as the largest minimal distance of all surface points 
of one structure to the points in the other structure.
intra-fraction patient setup variation
Intra-fraction setup variation was evaluated by computing the difference in patient posi-
tion after CBCT assisted patient setup (above) of the patient observed in the post-fraction 
CBCT scan. The pelvis bony anatomy was used as reference. For each fraction, the intra-
fraction patient motion was computed by first rigidly aligning the pre- and post-fraction 
CBCT scans to the planning CT using grey value matching in the XVI software (version 
4.5.1, Elekta, AB, Sweden). The registration clip box was defined around the bony pelvis 
in the planning CT scan. Rotations were converted to translations using the center of 
the clip box as correction reference point. The setup corrections as carried out by the 
Theraview Couch Setup Assistant (TCSA) (Cablon Medical, Leusden, The Netherlands) 
were subtracted from the calculated translations in the LR, AP, and CC directions. For 
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each patient, the mean intra-fraction setup change and the standard deviation were 
calculated for all directions. Then, the population mean (M), systematic (∑) and random 
changes (σ) of the intra-fraction patient setup were established. The systematic error (∑) 
defined the systematic population error and was calculated as the standard deviation 
of the distribution of the population mean (M). The random error (σ) was calculated as 
the root mean square of the patients’ random error, i.e. the standard deviation of each 
patient’s intra-fraction setup changes.
3.3 ReSuLTS
IMRT was delivered in 82.5% of the patients. Mean IMRT delivery time was 12.0 minutes. 
The mean time between the pre- and post-fraction CBCT scans was 20.8±3.2 minutes. In 
total 632 pre-and post-fraction CBCT scans were delineated.
Bladder volume increased on average by 62±55 ml over all treatment fractions and 
rectum volume increased on average by 5±33 ml. Bladder inflow rate was 3.0±2.7 ml/
min over all treatment fractions. Figure 1 shows the pre-fraction bladder volume and 
bladder volume difference with the mean and SD in all patients over 23 fractions. This 
figure indicates that the bladder volume as well as the bladder volume change reduces 
during the treatment course.
Fig re 1. For ach fr ction, the pre-fraction bladder volume (black) and the intra-fraction bladder 
volume change, averaged over all patients. The error bars equal one standard deviation of the 
average bladder volume or bladder volume change. 
 
 
 
 
 
 
 
 
Figure 1. For each fraction, the pre-fraction bladder volume (black) and the intra-fraction bladder volume 
change, averaged over all patients. The error bars equal one standard deviation of the average bladder 
volume or bladder volume change.
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A significant positive correlation was found between bladder inflow rate and volume of 
the bladder at the start of a fraction, as measured in the pre-fraction CBCT scan (R=0.44, 
p<0.01). This means that a larger bladder volume observed at the start of treatment was 
predictive of a higher inflow rate. Regression analysis showed a constant of 1.4 and a 
coefficient of 0.009, which means that for every 100 ml extra bladder volume at the start 
of treatment, the inflow rate increased with approximately 1 ml/min.
A significant correlation was found between bladder inflow rate and the average 
length of the cervix-uterus intra-fraction systematic displacement (R=0.6, p<0.01), 
meaning that the inflow rate could help predict cervix-uterus position during treat-
ment. The correlation of the cervix-uterus intra-fraction displacement was evaluated 
separately for the LR, CC, and AP direction as well and a significant correlation was found 
in the CC and AP (R=0.3, p<0.01 and R=0.6 p<0.01). There was no significant correlation 
between rectum filling and the average length of the cervix-uterus displacement nor for 
the displacements in the three directions separately.
The average Hausdorff distance of the intra-fraction registration accuracy was 1.1 mm, 
which shows that the registration of the cervix-uterus shapes was accurate.
The mean and the 5th and 95th percentiles of the systematic intra-fraction displace-
ments are depicted for each patient separately in figure 2. Table 1 summarizes these 
values averaged over the patient group. In the AP and CC direction the group-mean was 
significantly different from 0 (p<0.05), indicating a preferred direction for the systematic 
intra-fraction displacements. The filling of the bladder during the treatment fraction and 
the resulting cervix-uterus motion seems a plausible explanation. A similar trend was 
observed for the 5th and 95th percentiles in the AP and CC direction being asymmetrically 
distributed around 0 (AP: 0.5 to -5.8 mm; CC 4.9 to -0.8 mm). Figure 3 shows a color 
representation of the systematic intra-fraction displacements for each patient and for 
each direction separately. The figure demonstrates how the magnitude and direction 
of the systematic displacements is distributed across the cervix-uterus average shapes. 
Notwithstanding the inter-patient differences, the largest intra-fraction systematic 
displacements appear in the upper part of the uterus.
Table 2 shows the intra-fraction changes in patient setup for the patient group. Ap-
pendix 3A shows for each patient the mean and SD for each patient separately. When 
there was unexpectedly large motion in all directions, the image registrations were 
checked. Changes in bladder filling and flatulence were reasons for such patient motion. 
For all patients, the mean motion in CC and AP direction were smaller than 2.0 mm.
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Figure 2. The mean, 5th and 95th percentiles (error bars) intra-fraction cervix-uterus displacement for 
each patient in the a) Left-right, b) Cranial-caudal and c) Anterior-posterior directions. Positive values 
for LR, CC and AP pointed at motion in right, cranial and anterior directions, respectively. Some 
patients had due to bladder filling a large displacement in the LR, CC and AP direction, respectively.  
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Figure 2. The mean, 5th and 95th percentiles (error bars) intra-fraction cervix-uterus displacement for 
each patient in the a) Left-right, b) Cranial-caudal and c) Anterior-posterior directions. Positive values 
for LR, CC and AP pointed at motion in right, cranial and anterior directions, respectively. Some 
patients had due to bladder filling a large displacement in the LR, CC and AP direction, respectively.  
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Figure 2. The mean, 5th and 95th 
percentiles (error bars) intra-frac-
tion cervix-uterus displacement 
for each patient in the a) Left-right, 
b) Cranial-caudal and c) Anterior-
posterior directions. Positive values 
for LR, CC and AP pointed at motion 
in right, cranial and anterior direc-
tions, respectively. Some patients 
had due to bladder filling a large 
displacement in the LR, CC and AP 
direction, respectively.
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Table 1. Group-mean and standard deviation of the patients’ mean and the mean patients’ 5th and 95th 
percentiles of the systematic intra-fraction motion.
Cervix-uterus motion LR (mm) CC (mm) AP (mm)
Mean±SD 0.1±1.4 1.8±1.5 -2.8±1.8
95th percentile±SD 2.1±1.1 4.9±2.6 0.5±1.7
5th percentile±SD -2.3±2.4 -0.8±1.0 -5.8±2.7
Figure 3: A color representation of the systematic intra-fraction displacements in mm projected on 
each ati t’s average cervix-uterus shape. The first shape shows the average length of the intra-
fraction systematic displacements and the others show the systematic displacements in the LR, CC, 
and AP direction. The largest intra-fraction displacements often appear in the upper part of the 
uterus. 
 
 
 
Figure 3. A color representation of the systematic intra-fraction displacements in mm projected on each 
patient’s average cervix-uterus shape. The first shape shows the average length of the intra-fraction system-
atic displacements and the others show the systematic displacements in the LR, CC, and AP direction. The 
largest intra-fraction displacements often appear in the upper part of the uterus.
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Table 2. The overall mean (M), systematic error (S), and random error (s) of the intra-fraction changes in 
patient setup over the entire patient group .
Patient motion LR (mm) CC (mm) AP (mm)
M -0.1 0.4 1.1
∑ 1.3 0.4 0.6 
σ 1.4 1.0 1.1 
3.4 DiSCuSSion
To the best of our knowledge, this is the first study investigating the intra-fraction 
motion of the cervix-uterus of cervical cancer patients, using daily acquired pre- and 
post-fraction CBCT scans. Results showed that intra-fraction cervix-uterus motion is 
considerable in our treatment time frame of 20.4 minutes with group-mean systematic 
intra-fraction displacements of up to 5.8 mm to posterior and up to 4.9 mm to cranial 
(Table 1, 5th and 95th percentiles). Individual systematic displacements could even be 
larger and extend beyond 10 mm (Figure 2). From our previous studies, we learned that 
bladder filling has an impact on the position of the uterus (10,15). In this study, we also 
observed a significant correlation between bladder volume difference and intra-fraction 
cervix-uterus displacement (R=0.63, p<0.01). Rectum filling difference had no correla-
tion with the intra-fraction motion, which could be explained by the limited change in 
rectum filling during the treatment fraction.
In this study, the intra-fraction displacements were measured between the time points 
of the pre-fraction and post-fraction CBCT scan not knowing the actual displacement 
during dose delivery. An analysis to halfway through the dose delivery time of a fraction 
should give a more clinically relevant estimate of the intra-fraction motion. Bondar et al. 
demonstrated that cervix-uterus motion could be approximated by a linear function of 
the bladder filling (15). Furthermore, we assume that the filling of the bladder is linear in 
time as well. From our previous study, we learnt that the time needed for to match the 
CBCT to the planning CT scan is 1 minute, the time needed for plan selection and verifi-
cation is on average 2.4 minutes. If we would start measuring at halfway the CBCT scan 
acquisition and we would add the time needed to match the CBCT scan and for plan se-
lection, and determine the motion at the halfway mark of the average dose delivery time 
of IMRT (at 10.6 minutes), then the group-mean 5th and 95th percentiles will decrease 
from -2.3, 2.1 to -1.2, 1.1 mm in the LR direction, from -0.8, 4.9 to -0.4, 2.5 mm in the CC 
direction, and from -5.8, 0.5 to -3.0, 0.3 mm in the AP direction. Similarly, we calculated 
the 5th and 95th percentiles covering at least 90% of the patients at 10.6 minutes. These 
values (LR: -3.2, 2.0 mm; CC: -1.3, 5.0 mm; AP: -5.0, 1.5 mm) could be used as margins to 
account for the systematic intra-fraction motion. Note that in particular the margins in 
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the AP and CC directions are asymmetric. From October 2014 onwards, cervical cancer 
patients are treated in our institute by Volumetric Modulated Arc Therapy (VMAT) using 
the fully automated planning system Erasmus-iCycle (29). Consequently, average dose 
delivery time has been reduced from 12.0 minutes to 4.8 minutes. For VMAT treatments, 
following the same computation (at 7.0 minutes), the group-mean of the 5th and 95th 
percentiles would decrease to -0.8, 0.7 mm in LR, to -0.3, 1.6 mm in CC, and to -2.0, 0.2 
mm in AP direction, halfway through the dose delivery. The values covering at least 90% 
of the patients are LR: -2.1, 1.3 mm, CC: -0.8, 3.3 mm, and AP: -3.3, 1.0 mm.
For most patients, the largest motion was found at the uterine fundus. Therefore, if the 
fundus would be excluded from the clinical target volume, the margins to account for 
intra-fraction motion can be reduced. This is subject to future research.
As part of our current protocol we verified whether after the delivery of the selected 
IMRT plan, the CTV was still inside the PTV by inspecting each post-fraction CBCT. For 
all patients and all fractions, the CTV was observed inside the PTV (25). Hence, the ITVs 
combined with the 1-cm margin were sufficient to account for the intra-fraction motion.
This study extends on other research on this topic. Haripotepornkul et al. investigated 
the intra-fraction motion for cervical cancer patients with daily kV imaging throughout 
a course of IMRT using markers implanted into the cervix. A median marker displace-
ment of 2-4 mm was observed in any given direction, which is smaller than we analyzed, 
specifically in the AP direction. However, this could be explained because the markers 
represented the location of the cervix only, which is less affected by bladder filling 
changes than the uterus (27). Kerkhof et al. studied intra-fraction motion with and 
without registration of the bony anatomy using two or three offline MRI exams pre-
treatment and in week 1 and week 4 of the treatment. Four sagittal and four axial MRI 
scans were acquired over a time period of 16 minutes. They found that the midsagittal 
primary CTV could move more than 10 mm within a 16 minute time frame. They found 
a weak but significant correlation between bladder filling and CTV motion (26). This 
study was limited by the number of scans (2-3) per patient and by the analysis of the 
motion only in the midsagittal plane. Chan et al. also studied the intra-fraction motion 
of the cervix-uterus using three points of interest (cervical os, uterine canal, and uterine 
fundus). The largest motion was found at the fundus of the uterus with a mean of -1.1 
mm in AP direction and -3.1 mm in CC direction in a time frame of 31 minutes. This is 
smaller than we found, however, this could be explained by the fact that we included 
only patients with a large tip-of-uterus displacement measured pre-treatment in a full 
and empty bladder CT scan (28).
In bladder cancer patients, the intra-fraction motion has been investigated in several 
studies (32,33). Our study can be compared to the Dees et al. paper (32). They also used 
pairs of CBCT scans to analyze the intra-fraction motion. As opposed to our study, in 
this study two bladder filling protocols were used, one aiming at a full and one at an 
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empty bladder, i.e. patients were divided into two groups. They found a median bladder 
inflow rate over the whole patient population of 1.94 ml/min. Our results show that the 
bladder inflow rate was 3.0 ml/min over all treatment fractions. A more intensive drink-
ing protocol applied in our study may explain, besides other differences between the 
patient groups, the higher inflow rate seen for our patients.
A limitation of this study is that observer variability in contouring the cervix-uterus in 
CBCT scans may impact the results. To minimize this impact, the first author consistently 
delineated all pairs of CBCT scans. Contouring variability was further reduced using an 
automatic segmentation method as contouring aid (30). Furthermore, we would like to 
point out that we analyzed the scans pairwise, i.e. the pre-fraction and post-fraction 
CBCT scans for each fraction were compared. In this way, the impact reduced mainly to 
interpretation differences between a pre-fraction and a post-fraction CBCT scan. Also, 
the accuracy of the non-rigid registration of measuring the intra-fraction motion could 
be a potential source of error. However, we have seen that this error was small (<1.1 mm) 
and thereby it had limited influence on the observed intra-fraction motion.
In this study, we quantified the intra-fraction changes in cervix-uterus shape, bladder 
and rectum filling, and patient setup using pre- and post-fraction acquired CBCT scans. 
Intra-fraction changes in patient setup motion were small. Intra-fraction cervix-uterus 
motion was considerably larger and correlated with the intra-fraction filling of the blad-
der. Intra-fraction cervix-uterus motion should not be ignored, in particular in the design 
of Plan-of-the-Day strategies.
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AbSTRACT
background & purpose
It is unknown whether the historically found dosimetric advantages of treating gyneco-
logic cancer with the patient in a prone position with use of a small-bowel displacement 
device (belly-board) remain when volumetric arc therapy (VMAT) is used and whether 
these advantages depend on the necessary margin between clinical target volume 
(CTV) and planning target volume (PTV). The aim of this study is to determine the best 
patient position (prone or supine) in terms of sparing organs at risk (OAR) for various 
CTV-to-PTV margins and VMAT dose delivery.
Material & Methods
In an institutional review board approved study, 26 patients with gynecologic cancer 
scheduled for primary (9) or postoperative (17) radiation therapy were scanned in a 
prone position on a belly-board and in a supine position on the same day. The primary 
tumor CTV, nodal CTV, bladder, bowel and rectum were delineated on both scans. The 
PTVs were created each with a different margin for the primary tumor and nodal CTV. 
The VMAT plans were generated using our in-house system for automated treatment 
planning. For all margin combinations, the supine and prone plans were compared with 
consideration of all OAR dose-volume parameters but with highest priority given to 
bowel cavity V45Gy (cm3).
Results
For both groups, the prone position reduced the bowel cavity V45Gy, in particular for 
nodal margins ≥10 mm (∆V45Gy=23.9±10.6 cm3). However, for smaller margins, the ad-
vantage was much less pronounced (∆V45Gy=6.5±3.0 cm3) and did not reach statistical 
significance. The rectum mean dose (Dmean) was significantly lower (∆Dmean=2.5±0.3 Gy) 
in the prone position for both patient groups and for all margins, and the bladder Dmean 
was significantly lower in the supine position (∆Dmean=2.6±0.4 Gy) only for the postop-
erative group. The advantage of the prone position was not present if it needed a larger 
margin than the supine position.
Conclusion
For patients with gynecologic cancer, the historically found dosimetric advantages for 
the prone position remain for modern dose delivery techniques if large margins are 
needed. However, the advantage is lost for small margins and if the prone position 
needs a larger margin than the supine position.
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4.1 inTRoDuCTion
Radiation therapy is one of the standard modalities in gynecologic cancer treatment. 
Intensity modulated radiation therapy (IMRT) and volumetric arc therapy (VMAT) are 
both used to improve dose conformity and better spare the organs at risk (OARs) com-
pared with 3-dimensional conformal radiation therapy (3DCRT) (5,7,8,34). More recently, 
IMRT or VMAT has been combined with daily adaptive treatments (eg, plan library-based 
Plan-of-the-Day techniques) to further reduce the planning target volume (PTV) and to 
spare small bowel, which is considered the most important OAR (5,25). Dose to small 
bowel can also be reduced by setting patients up in a prone position on a small bowel 
displacement device (belly-board), pushing the small bowel outside the radiation field 
(5). However, the prone position has the known disadvantages of reduced cone beam 
computed tomography (CBCT) image quality resulting from breathing artefacts and re-
duced rotational stability (35); these may compromise treatment accuracy and thereby 
the feasibility of Plan-of-the-Day adaptive strategies. Moreover, the dosimetric advan-
tage of the prone position was mostly determined for 3DCRT or IMRT using relatively 
large margins (16,36-38). It is unknown to what extent those advantages remain when 
modern treatment planning and delivery techniques are used and how they depend on 
the PTV margin around the primary and nodal clinical target volume (CTV).
The aim of this work is twofold: (1) to determine whether the dosimetric advantages of 
the prone position found in the past remain for modern treatment planning and delivery 
techniques (ie, automatically generated dual-arc VMAT); and (2) to determine the impact 
of the CTV-to-PTV margins on OAR sparing and in particular to determine this impact on 
the supposed dosimetric advantage of the prone position.
4.2 MATeRiAL AnD MeTHoDS
Patient data
In this prospective study, 9 primary locally advanced cervical cancer patients with intact 
uterus, 10 postoperative locally advanced cervical cancer patients and 7 postoperative 
endometrial cancer patients were included. Given that the target volume in the patients 
with postoperative endometrial cancer and those with postoperative locally advanced 
cervical cancer was the same, we merged those groups for further analysis, making a 
total of 17 patients with postoperative gynecologic cancer.
All patients were scanned and treated in the Amsterdam Medical Center (AMC) from 
2011 to 2012 after providing written consent. The local ethics committee of the AMC 
approved this study.
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For each patient, 2 CT scans were made on the same day: a planning CT scan in prone 
position using a small bowel displacement device (belly-board) and immediately there-
after a CT scan in supine position, on a flat couch with a knee roll. Before scanning, 
patients were instructed to drink 500 cm3 after voiding the bladder 2 hours before the 
CT scan, aiming at a full bladder at the time of the scan.
In all CT scans of the patient with primary cervical cancer, the primary CTV (cervix, 
uterus and proximal part of the vagina) and the nodal CTV (common iliac lymph nodes, 
external iliac lymph nodes, internal iliac lymph nodes, presacral lymph nodes and para-
metrial tissue) were delineated. In addition, we delineated the bladder, rectum and bowel 
cavity. The latter encompassed all loops of small bowel, colon and sigmoid, including 
peritoneal space between the loops, starting caudally from the first bowel loop until 1 
cm above the PTV in the cranial direction according to the Radiation Therapy Oncology 
Group consensus guidelines (39,40). In all CT scans of the postoperative patients the 
bladder, bowel cavity (see above), rectum, primary CTV (proximal part of the vagina and 
paravaginal soft tissue), and nodal CTV were delineated. The contouring was performed 
by SH, GW, and NB. To minimize observer variation, all contours for both positions were 
checked for consistency by SH and JWM.
CTv-to-PTv margins for treatment planning
The PTV was created by an expansion of the primary 
CTV by 5, 10, or 20 mm and of the nodal CTV by 5, 7, 10, 
or 15 mm (41). Four different nodal PTV margins were 
combined with different primary PTV margins (Table 1). 
Here, we supposed that in clinical practice an accurate 
treatment of the primary CTV using, for example, a 
Plan-of-the-Day adaptive approach, is usually combined 
with an accurate treatment of the nodal CTV. Below, we 
explain the rationale of the margins used.
A 10 mm expansion of the nodal CTV is used in our cur-
rent clinical adaptive protocol as described in Heijkoop 
et al (25) and was used in the AMC in 2011 and 2012. In 
this study we combined the 10 mm nodal CTV margin 
with a primary CTV margin of 10 mm and 20 mm.
Ahmad et al (42) measured residual setup errors caused by rotation and nonrigid mo-
tion in cervical cancer treated in the prone position. They found that a 15 mm nodal PTV 
margin was needed to account for setup errors. In this study, we combined this nodal 
margin with a primary CTV expansion of 10 mm and 20 mm.
Finally, we investigated a 5 mm nodal PTV margin and combined this with a 5 mm and 
10 mm expansion of the primary CTV.
Table 1. Nine tested CTV-to-PTV 
margin combinations.
Margin around 
nodal CTv 
(mm)
Margin around 
primary CTv 
(mm)
5 5
5 10
7 5
7 10
7 20
10 10
10 20
15 10
15 20
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Automated plan generation
All VMAT plans were generated using a fully automatic method developed by Sharfo 
et al (29). The automated treatment plan generation was performed with our clinical 
treatment planning system (Monaco Version 5.0, Elekta AB, Sweden) based on an 
automatic pre-optimization with our in-house lexicographic multi-criterial optimizer, 
Erasmus-iCycle. Plan optimization with Erasmus-iCycle is based on an a priori defined 
“wish-list” containing hard constraints and prioritized objectives with assigned goal 
values. The wish list used in this study is clinically used at Erasmus MC. According to this 
wish list, patients are prescribed to receive 46 Gy in 2 Gy fractions. PTV coverage had 
the highest priority, followed by the sparing of the bowel cavity at V45Gy (i.e. the volume 
receiving ≥45 Gy). The V15Gy and mean dose (Dmean) of the bowel cavity, the rectum, and 
bladder were optimized with a lower priority. Pseudorings at different distances from 
the PTV were used to control the entrance dose in the patient and to create a conformal 
dose distribution. For further details on Erasmus-iCycle and automated planning we 
refer to Breedveld et al (20) and Sharfo et al (29). In another study from Voet et al (43), 
we showed that further improvements of the automatically generated VMAT plans by 
manually tweaking the plan objectives in Monaco led to only minor improvements in 
plan quality. All VMAT plans were visually checked and verified for clinical acceptability 
among others to ensure sufficient clearance for gantry rotation in prone position ac-
cording to standardized protocols by a clinician SH and a specialized RTT RF.
Dosimetric evaluation
The primary and the postoperative patients were analyzed both combined and sepa-
rately. For each patient, patient position, and for each primary/nodal margin combina-
tion, the absolute volume in cm3 of the bowel cavity receiving at least 45 Gy (V45Gy) was 
evaluated. We evaluated the absolute instead of the relative bowel cavity volume to 
reduce the impact of cranial contouring differences between the CT scans with the 
patient in the prone and supine position. The absolute volume was also found to be 
predictive for acute bowel toxicity in normal tissue complication probability models 
(44,45). For bladder and rectum, the Dmean was recorded. Because there is an inevitable 
time delay between the acquisition of the 2 CT scans, bladder filling may have increased 
in the second scan, potentially pushing the small bowel farther outside the high-dose 
region, or bladder filling may have decreased if the patient had to void her bladder 
in between the acquisitions. To verify the effect on the prone-supine comparison, we 
tested whether a difference in V45Gy of the bowel cavity between the prone and supine 
position was related to the bladder volume difference between both scans. The PTV95% 
(volume of the PTV receiving ≥43.7 Gy) was calculated to verify PTV coverage. A paired 
2-sided Wilcoxon signed rank test was used to compare both patient positions, and P-
values <0.05 were considered statistically significant. SPSS Statistics 21.0 was used for 
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all statistical analyses. To determine the sensitivity to the needed margin, we not only 
compared supine with prone treatment plans, with matching margin combinations but 
also compared supine with prone plans for which the prone plans had a larger margin 
around the nodal CTV than did the supine plans. In that way, we assessed the scenario 
that for prone positioning a larger nodal margin is needed (ie, to compensate for uncor-
rected rotation errors) (42).
4.3 ReSuLTS
PTv coverage
The V95% of the PTV was >99% for all 9 margins and for both patient positions. All 
treatment plans of all patients were verified and found to be clinically acceptable and 
deliverable.
bowel cavity sparing and impact of margins
All patients
The mean total bowel cavity volume was 1088±397 cm3 (1 SD) for patients in the prone 
position and 1601±489 cm3 for patients in the supine position. Figure 1a shows the com-
parison between the supine and prone position in terms of V45Gy of the bowel cavity for 
all patients and all matching primary/nodal margin combinations. The prone position 
was significantly superior for large nodal margins ≥10 mmbut not for the nodal margins 
of 5 and 7 mm. Table 2 lists the differences in V45Gy of the bowel cavity for each matching 
margin combination. The significant advantage was not present if the prone position 
needed a larger margin than the supine position. In the latter case, the supine position 
was always significantly better, except for 1 margin combination (supine 20/7mm vs 
prone 20/10mm) (Figure 1b). Figure 2 shows the dependence of the bowel cavity V45Gy 
on the nodal margin for both positions, where for nodal margins ≥10 mm the prone 
position was significantly better than the supine position. Additional data can be found 
for the V15Gy and Dmean of the bowel cavity in Appendix 4A.
Primary group
The mean bowel cavity volume was 1005±351 cm3 for patients in the prone position and 
1484±521 cm3 for patients in the supine position. Figure 3a illustrates the bowel cavity 
V45Gy for this patient group for all matching margin combinations. This figure indicates 
that when small margins were used, the advantage for either prone or supine is not sig-
nificant and that when larger margins were used (10/10mm, 10/15mm, and 20/15mm), 
the prone position was significantly better. Table 2 summarizes the differences in bowel 
cavity V45Gy and significance between the supine and prone position for all margin com-
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Figure 1a. Comparison of bowel cavity V45Gy (cm3) for supine and prone position for matching 
primary/nodal margin combinations for both groups combined. Codings for the primary/ nodal 
margins are shown. Prone was significantly superior to supine for margin combinations ≥10/10 mm. 
 
 
 
Figure 1a. Comparison of bowel cavity V45Gy (cm3) for supine and prone position for matching primary/
nodal margin combinations for both groups combined. Codings for the primary/nodal margins are shown. 
Prone was signifi cantly superior to supine for margin combinations ≥10/10 mm.
Figure 1b. For all patients, comparison of different scenarios between supine nodal margins and 
lar e  prone nodal margins in terms of bowel cavity V45Gy. The first number indicates the prone 
margin; the second, the supine margin.  
 
 
 
 
 
 
 
Figure 1b. For all patients, comparison of diff erent scenarios between supine nodal margins and larger 
prone nodal margins in terms of bowel cavity V45Gy. The fi rst number indicates the prone margin; the sec-
ond, the supine margin.
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binations. Figure 3b shows again the bowel cavity V45Gy but then comparing margin 
combinations of which the nodal margin was larger in the prone position. These results 
indicate that in these combinations there was no preference in patient position. For all 
9 margins, we did not find any significant correlation between difference in V45Gy of the 
bowel cavity and the difference in bladder volume.
Table 2. For both patient groups separately and combined, the dosimetric differences (OARs) between 
prone and supine position for matching primary/nodal margin combination. Positive values indicate that 
the prone position is superior.
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5/5 mm
Mean±SD
P-value
-2.1±0.5
<0.001*
-1.9±1.3
0.05
-2.2±0.2
0.001*
2.5± 0.3
<0.001
3.3±1.2
0.01
2.1±0.4
0.006
3.8 ±1.0
0.3
5.8±2.0
0.4
2.4±0.7
0.7
5/7 mm
Mean±SD
P-value
-2.1±0.4
<0.001*
-1.6±1.2
0.1
-2.4±0.1
0.001*
2.5±0.2
<0.001
3.3±0.8
0.008
2.0±0.4
0.02
5.9±0.8
0.3
7.6±0.1
0.4
5.1±0.6
0.5
10/5 mm
Mean±SD
P-value
-2.2±0.4
<0.001*
-1.5±1.2
0.1
-2.5±0.0
0.001*
2.8±0.2
0.001
3.9±0.8
0.008
2.1±1.0
0.03
5.6±0.2
0.2
12.1±3.6
0.1
2.2±1.1
0.4
10/7 mm
Mean±SD
P-value
-2.4±0.6
<0.001*
-1.7±1.7
0.07
-2.7±0.2
<0.001*
2.5±0.0
0.001
3.4±0.9
0.008
2.0±0.7
0.03
10.7±0.1
0.07
16.5±2.4
0.09
7.7±0.0
0.3
10/10 mm
Mean±SD
P-value
-2.0±0.4
<0.001*
-1.4±1.3
0.1
-2.4±0.0
0.001*
2.3±0.2
0.02
3.7±0.5
0.008
1.5±0.3
0.08
15.1±1.3
0.05
23.8±2.0
0.04
10.4±0.5
0.3
10/15 mm
Mean±SD
P-value
-1.9±0.4
0.001*
-1.3±0.8
0.2
-2.2±0.2
0.001*
2.1±0.1
0.001
2.7±0.4
0.01
1.8±0.5
0.02
33.5±2.2
0.04
40.7±4.3
0.03
29.7±2.0
0.04
20/7 mm
Mean±SD
P-value
-2.9±0.7
<0.001*
-2.0±1.4
0.09
-3.4±0.2
<0.001*
2.7±0.9
<0.001
2.7±0.1
0.008
2.7±1.2
0.01
13.5±4
0.2
26.2±11.5
0.09
6.7±0.9
0.5
20/10 mm
Mean±SD
P-value
-2.5±0.7
<0.001*
-1.7±1.4
0.09
-2.9±0.2
<0.001*
4.0±2.0
<0.001
2.5±0.0
0.008
2.7±1.1
0.004
21.1±0.6
0.04
32.5±9.9
0.07
15.1±2.2
0.1
20/15 mm
Mean±SD
P-value
-2.1±0.5
<0.001*
-1.6±1.3
0.1
-2.4±0.1
<0.001*
2.2±0.7
<0.001
1.9±0.2
0.008
2.3±0.9
0.002
36.6±3.2
0.04
46.7±8.1
0.04
31.2±4.7
0.04
*Supine position is superior
Positive values indicate that the prone position is superior.
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Postoperative group
The mean bowel cavity volume was 1132±423 cm3 in the prone position and 1663±476 
cm3 in the supine position. Figure 4a shows the bowel cavity V45Gy for both positions and 
all matching margin combinations. For this group, the prone position better spared the 
bowel cavity than did the supine position, in particular for large margins: 10/15mm and 
20/15mm. For small margins, the advantage was less pronounced and did not reach 
statistical significance. Figure 4b illustrates the comparison for different nodal margins. 
Assuming that a smaller margin is needed in the supine position, supine is significantly 
better for sparing the bowel cavity.
bladder
All patients
The mean bladder volume was 273±138 cm3 for patients in the prone position and 
313±176 cm3 for patients in the supine position. Four patients had to void the bladders 
after the acquisition of the CT scan in prone position. For the other 22 patients’ blad-
der volume increased on average by 92.2 cm3 between the 2 scans. For all margins, the 
bladder Dmean was significantly lower in the supine position (average Dmean of 37.8 Gy in 
prone position; 35.6 Gy in supine position). In Appendix 4B the V40Gy of the bladder can 
be found.
Primary group
The average volume was 313±136 cm3 for patients in the prone position and 308±191 
cm3 in the supine position. There was no significant difference in Dmean between patients 
in the prone position and those in the supine position (Table 2).
Figure 2. Dependency of the nodal margin on the bowel cavity V45Gy (cm3) for supine and prone 
position, for all patients. The first number indicates the primary margin; the second number 
indicates the nodal margin. The circles indicate the prone position; the squares indicate the supine 
position. 
 
 
 
Figure 2. Dependency of the nodal margin on the bowel cavity V45Gy (cm3) for supine and prone position, 
for all patients. The first number indicates the primary margin; the second number indicates the nodal mar-
gin. The circles indicate the prone position; the squares indicate the supine position.
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Figure 3a. Comparison of bowel cavity V45Gy (cm3) for supine and prone position for matching 
primary/nodal margin combinations for the primary group only. Codings for the primary/nodal 
margin combinations are shown. Prone was significantly superior to supine for the larger margin 
combinations (10/10 mm, 10/15 mm, and 20/15 mm). 
 
 
 
 
Figure 3a. Comparison of bowel cavity V45Gy (cm3) for supine and prone position for matching primary/
nodal margin combinations for the primary group only. Codings for the primary/nodal margin combina-
tions are shown. Prone was signifi cantly superior to supine for the larger margin combinations (10/10 mm, 
10/15 mm, and 20/15 mm).
Figure 3b. For the primary group, comparison of different scenarios between supine nodal margins 
and larger prone nodal margins in terms of bowel cavity V45Gy. The first number indicates the prone 
margin; the second, the upine margin.  
 
 
 
Figure 3b. For the primary group, comparison of diff erent scenarios between supine nodal margins and 
larger prone nodal margins in terms of bowel cavity V45Gy. The fi rst number indicates the prone margin; the 
second, the supine margin.
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Figure 4a. Comparison of bowel cavity V45Gy (cm3) for supine and prone position for matching 
primary/nodal margin combinations for the postoperative group only. Codings for the primary/nodal 
margin combinations are shown. Prone was significantly superior to supine for the larger margin 
combinations (10/10 mm, 10/15 mm, and 20/15 mm). 
 
  
 
 
Figure 4a. Comparison of bowel cavity V45Gy (cm3) for supine and prone position for matching primary/
nodal margin combinations for the postoperative group only. Codings for the primary/nodal margin com-
binations are shown. Prone was signifi cantly superior to supine for the larger margin combinations (10/10 
mm, 10/15 mm, and 20/15 mm).
Figure 4b. For the postoperative group, comparison of different scenarios between supine nodal 
margins and larger prone nodal margins in terms of bowel cavity V45Gy. The first number indicates 
the prone argin; the second, the supine margin.  
 
 
Figure 4b. For the postoperative group, comparison of diff erent scenarios between supine nodal margins 
and larger prone nodal margins in terms of bowel cavity V45Gy. The fi rst number indicates the prone margin; 
the second, the supine margin.
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Postoperative group
The average bladder volume was 251±139 cm3 for patients in the prone position and 
316±174 cm3 in the supine position. The bladder was significantly fuller in the supine 
position. Table 2 shows the mean difference in bladder Dmean for each matching margin 
combination. It illustrates that the Dmean for patients in the supine position was signifi-
cantly lower.
Rectum
All patients
The average rectum volume was 114±61 cm3 for patients in the prone position and 93±40 
cm3 for patients in the supine position. No significant difference was found between 
the prone and supine position for the rectum volume. For all margin combinations, the 
rectum Dmean was significantly lower for patients in the prone position (average Dmean of 
37.4 Gy in prone position; 39.9 Gy in supine position). In Appendix 4B the V40 Gy of the 
rectum is given.
Primary group
The mean volume of the rectum was 143±80cm3 for patients in the prone position 
and 78±28cm3 for patients in the supine position. The Dmean was significantly lower for 
patients in the prone position (3.2±0.9 Gy) than for those in the supine for all margin 
combinations (Table 2).
Postoperative group
The mean rectum volume was 99±45cm3 for patients in the prone position and 
101±44cm3 for patients in the supine position. The Dmean for patients in the prone posi-
tion was significantly lower (2.2±0.4 Gy) than for patients in the supine position, except 
for the margin combination 10/10 mm (Table 2).
4.4 DiSCuSSion
In this report, we present a rigorous treatment planning comparison study to determine 
the optimal patient position for VMAT dose delivery and for various CTV-to-PTV margins 
in gynecologic cancer patients. We considered the bowel cavity as the OAR that should 
be spared as the most needful of adequate target coverage. For the whole group and 
for both primary and postoperatively treated groups separately, the prone position was 
significantly superior in bowel cavity sparing when large margins were used around 
the nodal target; ≥10/10 mm (primary/nodal margin around CTV) for the whole group, 
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≥10/10 mm for the primary group, and ≥10/15 mm for the postoperative group (Figure 
1a, 3a, and 4a). To determine the sensitivity of the dosimetric difference to the margin 
needed for the supine and prone position, we compared not only the prone-to-supine 
plans with matching margins but also the prone–to-supine plans, for which the supine 
plans had a smaller margin than the prone plans (Figure 1b, 3b and 4b). If in prone posi-
tion a larger margin around the nodal CTV is needed due to e.g. an increased rotational 
instability (42,46), supine would be the preferred patient position.
For both primary and postoperative patients, the prone position was significantly bet-
ter for the rectum Dmean. This difference could not be explained by significant anatomical 
differences regarding the rectum volume and CTV, which were inspected visually. A 
possible explanation for the difference could be that the prioritization of reducing the 
dose to the bowel cavity had a stronger impact on the sparing of the rectum in the 
supine position compared with the prone position (29). A study by Nijkamp et al(47) 
showed that the rectum volume also differed between the prone and supine position 
for rectal cancer patients . In the postoperative group, the bladder Dmean was significantly 
lower for patients in the supine position (2.6 Gy). This can be explained by the fact that 
in this group the bladder was significantly fuller in the CT scans of patients in the supine 
position.
Our results also showed that increased margins around the nodal CTV had a large 
effect on the V45Gy of the bowel cavity. Consequently, reducing these margins could 
potentially reduce small bowel related side effects.
Stromberger et al (38) showed in a dosimetric study that IMRT to patients in the prone 
position reduces small bowel volume at doses > 20 Gy. The main differences with our 
study were that the relative volume for all OARs was evaluated and that only 1 margin 
was used for planning (ie 10 mm for the primary and nodal CTV, which is most compa-
rable with a 15 mm margin in our study because of differences in CTV-to-GTV definition). 
In our study, for margin combinations ≥10/10 mm, we also found a significant difference 
between the prone and supine position. Pinkawa et al (37) evaluated postoperative 
patients only and recommended a prone patient position to protect the small bowel. 
However, in that study a 4-field box technique was used, which in terms of conformity 
could be compared with our VMAT plans with large margins. For this group we found 
that the prone position was also superior. Finally, Adli et al (36) showed that the prone 
position reduces the small bowel dose for large margins, but did not evaluate the benefit 
for small margins.
The question remains whether our findings based on automated treatment planning, 
a system unavailable to most clinics, are relevant to the rest of the world. In a validation 
study (43), automatically generated VMAT plans were dosimetrically compared with 
manually generated plans made by expert planners. Those results showed that the 
automatically generated treatment plans were non-inferior to the manually generated 
Chapter 4
54
treatment plans. Moreover, it was shown that additional manual adjustments of the au-
tomatically generated treatment plans led to only minor improvements in plan quality.
A limitation of the current study is that the bladder volume differed between the CT 
scans of patients in the supine and prone position. This difference is inevitable because 
of the time interval between the acquisition of the supine and prone CT scan. To de-
termine the impact of the bladder volume difference, we related this to the difference 
in V45Gy between prone and supine, but found no significant correlation. The number 
of primary patients was low, however, all results were found to be consistent across 
patients and patient groups.
Apart from dosimetric differences between the supine and prone position, other 
variables should also be taken into account in the choice of an optimal position. A belly-
board, used for treatment of a patient in the prone position, usually does not fit into 
an MRI scanner. Therefore, MRI scans are usually acquired without a belly-board and 
often with the patient in a supine position. If the planning CT scan is also obtained with 
the patient in a supine position, image fusion will be simpler. Furthermore, with the 
patient in a prone position, respiratory-induced patient motion blurs the CBCT images 
and causes streaky artefacts. Possibly the supine position is also less susceptible to rota-
tional errors and more comfortable for the patient (42,46). Another important factor that 
must be taken into account is that with the introduction of online adaptive radiation 
therapy techniques smaller margins can be used. This means that the potential benefit 
on sparing the bowel cavity when the patient is in a prone position will be lost if small 
margins are used. Based on the data reported in this study and for the practical purposes 
mentioned above, our recommendation is to treat patients in a supine position if daily 
image guidance enables the safe use of margins ≤10 mm. If larger margins are a prereq-
uisite, prone positioning still remains of benefit for bowel-sparing purposes. We expect 
the greatest benefit from more complex techniques that enable a safe margin reduction 
in reducing the dose to the small bowel and consequently in reducing gastrointestinal 
toxicity (44). Whether the dose reductions translate into a clinically observable benefit 
is part of ongoing research.
It is concluded that the historically found dosimetric advantages of the prone position 
remain for modern dose delivery techniques with large margins. However, this advan-
tage is lost for small margins and in case the prone position needs a larger margin than 
the supine position.
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AbSTRACT
background and purpose
For locally advanced cervical cancer patients, treated with External Beam Radiotherapy 
(EBRT), Quality of Life (QoL) questionnaires are frequently used to evaluate treatment-
related symptoms and functioning scales. Currently, it is unknown how those evolve 
during the radiation treatment course. In this prospective study we report on weekly-
captured patient-reported QoL and symptoms during image-guided adaptive radio-
therapy (IGART) of cervical cancer patients.
Material and Methods
Between January 2012 and September 2016, all locally advanced cervical cancer patients 
treated with IGART and brachytherapy with or without chemotherapy or hyperthermia, 
were eligible. QoL was assessed at baseline; weekly during the first five weeks of treat-
ment; 1 week, 1 and 3 months after treatment, using the EORTC QLQ-C30 and the QLQ-
CX24 questionnaires. Comparisons were made with an age-matched norm population.
Results
Among the 138 (70%) responders, most symptoms showed a moderate-to-large 
increase, reaching a maximum at the end of treatment, or first week after treatment 
with return to baseline value at 3 months after treatment. While most symptoms gradu-
ally increased during the first five weeks, diarrhea and bowel cramps already markedly 
increased within the first three weeks to reach a plateau at the 5th week of treatment. 
Global health and functioning were temporarily decreased and returned to a plateau at 
baseline level 3 months after treatment, except for cognitive functioning.
Conclusion
A profound impact on QoL was observed during the radiation treatment course, tem-
porarily affecting functioning. The maximum impaired was reached at the end of EBRT.
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5.1 inTRoDuCTion 
Standard treatment for locally advanced cervical cancer is external beam radiation 
therapy (EBRT) combined with concurrent chemotherapy and brachytherapy. Confor-
mal dose distributions resulting from Intensity Modulated Radiation Therapy (IMRT) or 
Volumetric Modulated Arc Therapy (VMAT) have markedly reduced dose to organs at 
risks (OARs), compared to conventional 3D conformal radiotherapy (3DCRT), and less 
side-effects are reported (7,8,12,48). However, interfraction motion of the uterus and 
cervix, due to variations in bladder or bowel filling, still necessitates a considerable 
safety margin. This results in unwanted exposure to OARs, which may translate to more 
patient reported symptoms and impaired Quality of Life (QoL) (13,25,27,49).
Quality of Life questionnaires are a frequent used measurement tool in order to 
evaluate treatment related symptoms and functioning scales after EBRT for cervical 
cancer. Many studies report on QoL at baseline and 3 months – 5 years after treatment 
to determine long-side effects (50-55). The main conclusion in these studies is that 3 
months after treatment most symptoms and functioning scales are returned to base-
line value levels again, however, toxicity tends to increase again from one year after 
treatment. Especially gastro-intestinal, genito-urinary and vaginal/ sexual problems, 
that impact on the Quality of Life (QoL) are of concern (55,56). Though, despite these 
studies it is still unknown what the dynamics are during the acute treatment phase, 
and which symptoms and functioning scales are most impaired in the first 5 weeks. In 
order to fill this gap in current literature, the aim of this prospective analysis was to 
evaluate patient reported QoL and symptoms weekly during treatment to measure 
the dynamics of the acute phase among locally advanced cervical cancer patients 
treated with an image-guided online adaptive radiotherapy (IGART) technique using 
small margins. QoL questionnaires were used from locally advanced cervical cancer 
patients treated with IGART using a Plan-of-the-Day approach (25). Main goal of the 
PotD approach is to reduce toxicity using small margins and online image guidance. 
Using the QoL questionnaires of the PotD approach, a detailed analysis of the acute 
phase of the radiation treatment (the first 5 weeks until 3 months after treatment) 
is presented for locally advanced cervical cancer patients treated with a modern ra-
diotherapy technique. Comparisons were made with an age-matched healthy (norm) 
population. In order to facilitate comparisons with literature, we also report our initial 
results up to one year after treatment.
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5.2 MATeRiAL AnD MeTHoDS
From January 2012 onwards, all locally advanced cervical cancer patients who were 
treated at the Erasmus MC Cancer Institute according to a PotD approach were asked 
to participate in this study and written informed consent was obtained (25). The ques-
tionnaires were part of routine clinical practice and therefore, the hospital local ethics 
committee granted us a waiver from needing ethical approval for using this data.
Treatment
For all patients, radiotherapy was combined with either chemotherapy or hyperthermia 
depending on FIGO stage (4). Patients with small tumors up to FIGO stage IB2 were 
treated with radiotherapy alone. Patients with higher staged disease received concur-
rent chemoradiation (5 cycles of cisplatin 40mg/m2 body surface). Hyperthermia was 
considered if cisplatin was contra-indicated (57). Patients with very bulky tumors and/ 
or large nodal disease or para-aortic nodal disease received neoadjuvant chemotherapy 
(cisplatin 70mg/m2 body surface, given in 6 six schedules) followed by radiotherapy and 
hyperthermia.
The PotD approach has been previously described (25). In brief, four polymer-based 
markers were implanted during the gynecological examination under anesthesia, to be 
used for daily localization of the cervix during treatment. Before and during treatment, 
all patients were requested to follow a drinking protocol aiming at a moderately full 
bladder. Since May 2014 rectum laxation was added to the CT scan protocol. Using a full 
and empty bladder treatment planning CT scans, Internal Target Volumes were made 
of the primary target volume (consisting of GTV, cervix, uterus and proximal part of the 
vagina) for creation of the plan library. Patients with large cervix-uterus motion (‘mov-
ers’; >2.5 cm as measured at the tip of the uterus), had two IMRT/ VMAT plans, one for 
an empty-to-half-full and one for a half-full-to-full bladder range. Patients with small 
motion (‘non-movers’) had one IMRT/VMAT plan, covering the whole range from empty 
to full. Planning Target Volumes were created using a 1-cm expansion of the combined 
nodal CTV and the generated ITVs. All patients had a motion robust 3D-conformal or 
VMAT backup plan using generous margins (25). Daily Cone Beam CT scan was used for 
plan selection. All patients received 46 Gy in 23 fractions or 48.6 Gy in 27 fractions in 
case of extended field irradiation. MRI guided high dose rate brachytherapy was given 
in 3 applications (7 Gy). In a minority of patients CT was used or 2 applications (8.5 Gy) 
were delivered using an intracavitary technique with or without combined interstitial 
technique. A nodal boost was given in case of pathological lymph nodes. Intention was 
to have the overall treatment time < 7 weeks.
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Quality of Life 
Patient reported QoL and symptoms were prospectively assessed at the following time 
points: before start of treatment (baseline); every week during treatment; 1 week and 1, 
3, and 6 months after treatment and then every 6 months up to 5-years. The European 
Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the QLQ-CX24 
questionnaires were used. The QLQ-C30 questionnaire is used for all cancer sites (58), and 
consisted of a global health status scale, 5 functional scales (physical, role, emotional, 
cognitive and social functioning), 3 symptom scales (fatigue, pain, nausea and vomiting) 
and 5 single-item symptoms (dyspnea, loss of appetite, insomnia, constipation and diar-
rhea). The EORTC QLQ-CX24 questionnaire is a cervical cancer specific module consist-
ing of 3 scales (symptom experience, body image and sexual/vaginal functioning) and 
6 single-item symptoms (lymphedema, peripheral neuropathy, menopausal symptoms, 
sexual worry, sexual activity and sexual enjoyment) (59). Patients filled out the question-
naires using a link provided with email or on a paper version.
Statistical analysis 
Patients were included as responders in this prospective study, if they had returned 
the baseline or the first week of treatment and at least 1 additional questionnaire. This 
analysis included questionnaires up to one year after treatment. Patients were censored 
for QoL analysis at time of progression or in case of stable disease requiring salvage 
hysterectomy.
Analysis of the symptoms and scales was done using the provided EORTC guidelines 
(59,60). All 4-7 point Likert-type response scales were linearly converted to 1-100 scores. 
A higher score represents either a better level of functioning or a higher level of symp-
toms.
Differences in scores were required to be both statistical significant (p-value <0.01, 
to account for multiple testing) and had to fulfill criteria of minimal clinical relevance. A 
non-parametric Mann-Whitney test was used to compare mean scores between different 
time points or between the study and norm populations. When applicable, the published 
consensus guidelines for small, medium and large clinically significant differences of the 
EORTC QLQ-C30 was used (61); otherwise the difference was considered small (5-10), 
medium (10-20) or large (>20) according to Osoba et al (62). Scores were compared to a 
Dutch female norm population (N=1424) from 2012 (sexual items in N=950 from 2011) 
that was matched for age using a linear regression. The Dutch norm population data 
was obtained with permission of the profiles registry (63). The Armitage Trend Test and 
Spearman Rho were used to evaluate the impact of different characteristics on single 
item symptoms of diarrhea and dysuria. Statistical analysis was performed using SPSS 
version 21.0.
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5.3 ReSuLTS
From January 2012 until September 2016 a total of 197 locally advanced cervical cancer 
patients were treated with a PotD protocol, of which 138 (70%) were included as re-
sponders in this QoL analysis. Questionnaire return rates at each time point and reasons 
for non-response are depicted in Appendix 5A. In 97.5% of the patients the question-
naires were filled in completely; in 1.9% one question was missing and in 0.6% two or 
more questions were missing.
There were no significant differences in patient and treatment characteristics of 
responders versus non-responders. Patient and treatment characteristics are summa-
rized in Table 1. The median age of the responders was 51.6 years (range 25 – 86) and 
the majority of patients had FIGO stage IIB or higher (75.4%) and received concurrent 
chemoradiation (53.6%). In 68.1% of the patients, the plan library contained a single 
IMRT/ VMAT plan (‘non-movers’), and in 31.9% the plan library contained two IMRT/ 
VMAT plans, apart from the motion robust backup plan. Overall treatment time was < 7 
weeks for 90% of the patients. The main reason for a longer treatment time was delivery 
of a sequential nodal boost.
Table 1. Patient, tumor and treatment characteristics (n=138 responders)
no. %
Age
Median, years (range) 51.6 (25 – 86)
Marital status
Married 68 48.9
Partner 27 19.4
Single 43 30.9
Children
Yes 111 80.4
No 27 19.6
employment
Employed 81 58.7
Unemployed 37 26.8
Retired 20 14.5
Charlson score/ comorbidity*
0 88 63.8
1 38 27.5
2 7 5.1
3 5 3.6
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Table 1. Patient, tumor and treatment characteristics (n=138 responders) (continued)
no. %
FiGo stage
1B1 17 12.3
1B2 10 7.2
IIA 7 5.1
IIB 87 63.0
IIIA 3 2.2
IIIB 10 7.2
IVA 2 1.4
IVB 2 1.4
Histological type
Squamous cell carcinoma 119 86.2
Adenocarcinoma 14 10.1
Other 5 3.6
brachytherapy first fraction°
Week 4 90 65.2
Week 5 36 26.0
After EBRT 6 4.3
nodal boost
Yes 60 43.5
No 78 56.5
Treatment
CT + RT 74 53.6
NACT + RT + HT 26 18.8
RT + HT 26 18.8
RT alone 12 8.7
Motion#
Mover 44 31.9
Non mover 94 68.1
Treatment position
Prone 94 68.1
Supine 44 31.9
*The most frequent co-morbidity was cardiovascular (31.2%) followed by chronic disease (21.7%), COPD 
(6.5%) and diabetes (6.0%).
#Motion: mover: tip of uterus movement of more than 2.5 cm as measured between a full and empty blad-
der CT scan
° 6 patients received no brachytherapy because of uterus perforation or the tumor was too large. Abbrevia-
tions: CT+RT=chemoradiation (5 weekly courses of cisplatin 40mg/m2 body surface), NACT = neoadjuvant 
chemotherapy (6 courses of cisplatin 70mg/m2 body surface) followed by concurrent radiotherapy and 
hyperthermia, RT+HT=concurrent radiotherapy and hyperthermia, RT alone = radiotherapy alone
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Functioning
Scores of EORTC QLQ-C30 functioning and global health scales are shown in Table 2 and 
Figure 1.
The following described differences or changes in scores were both clinical relevant 
and statistical significant. At baseline, scores of all functional scales except global health 
status were lower compared to the age-matched norm population. At week five of treat-
ment, global health, role, social and physical functioning showed a medium decrease; 
cognitive functioning was small decreased, while emotional functioning was stable. All 
functioning scores returned to a plateau at baseline level 3 months after treatment, ex-
cept for cognitive functioning that after a temporary improvement at 3 months showed 
a small decrease again 1 year after treatment. Compared to the norm population all 
functioning scores, except global health showed either a small decrease or a medium 
decrease (cognitive functioning) 1 year after treatment.
Figure 1a. Patient functioning scales (0 – 100) from European Organization for Research and 
Treatment of Cancer C30 questionnaire (EORTC QLQ-C30). At 3 – 6 months after treatment the global 
health status returns to the baseline score. Mean ± 95% confidence intervals between 40 and 100 are 
shown. The dotted line indicates reference values from an age-matched Dutch female population 
cohort.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a. Patient functioning scales (0 – 100) from European Organization for Research and Treatment 
of Cancer C30 questionnaire (EORTC QLQ-C30). At 3 – 6 months after treatment the global health status 
returns to the baseline score. Mean ± 95% confidence intervals between 40 and 100 are shown. The dotted 
line indicates reference values from an age-matched Dutch female population cohort.
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Symptoms and sexual functioning
Scores of symptoms and sexual functioning are provided in Table 2 (QLQ-C30), Table 3 
(CX-24) and Figures 2 and 3; in addition, patient responses (none, a little, quite a bit, very 
much) for all symptom items are provided in Appendix 5B.
At baseline, a small increase of fatigue, nausea/ vomiting, constipation, appetite loss and 
financial difficulties was observed compared to the norm population, while diarrhea, in-
somnia, dyspnea and pain symptoms were in range. During the first five weeks of treatment, 
a large increase was observed for bowel cramps, dysuria, irritated/sore vagina, and fatigue; 
a medium increase for diarrhea, nausea/vomiting, fecal leakage, difficulties voiding, meno-
pausal symptoms and pain; a small increase for urinary frequency, tingling/numbness, ap-
petite loss, insomnia and dyspnea; in contrast a small decrease was found for constipation. 
Figure 1b. Symptom scales (0 – 100) from the EORTC QLQ-C30. Mean ± 95% confidence intervals 
between 0 and 60 are shown. The dotted line indicates reference values from an age-matched Dutch 
female population cohort.  
 
 
Figure 1b. Symptom scales (0 – 100) from the EORTC QLQ-C30. Mean ± 95% confidence intervals between 
0 and 60 are shown. The dotted line indicates reference values from an age-matched Dutch female popula-
tion cohort.
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While most symptoms gradually increased during the first five weeks, diarrhea and 
bowel cramps already markedly increased within the first three weeks to reach a plateau 
at the 5th week of treatment. All symptoms that were increased at the end of treatment 
decreased again during the first 3 months after treatment. While several symptoms still 
remained elevated up to one year after treatment compared to baseline values (diarrhea, 
bowel cramps, fecal leakage, dysuria, pain, insomnia, tingling/numbness, menopausal 
symptoms), others decreased compared to baseline level (nausea/vomiting, constipation, 
appetite loss, urinary frequency). In addition, several symptoms became apparent 1 to 4 
weeks after treatment and remained at a moderately increased level throughout the first 
year after treatment (urinary leakage, sexual/vaginal symptoms scale and components: 
vaginal dryness, short / tight vagina and pain during intercourse). Finally, a small decrease 
in vaginal discharge and abnormal blood loss became apparent during treatment and 1 to 
4 weeks after treatment and remained up to one year after treatment.
The increased vaginal symptoms were paralleled by increased sexual worrying and 
decreased sexual enjoyment. In contrast, sexual activity gradually increased from 6 
months after treatment. At baseline 21% were sexually active to any degree compared 
to 55% and 61% at 6 and 12 months, respectively.
influence of treatment characteristics
Symptoms of diarrhea and dysuria showed the largest increase in the first five weeks 
of treatment (see above). Different patient and treatment characteristics (nodal boost, 
movers vs non-mover, treatment type, para-aortic irradiation, PTV volume, treatment 
position, use of backup plan) were evaluated for their impact on diarrhea and dysuria 
(see Appendix 5C). No significant prognostic factors could be found for any characteris-
tic. The total PTV was not significantly correlated with the outcome of diarrhea (p=0.8) 
and dysuria (p=0.6) in the 5th week of treatment.
5.4 DiSCuSSion
This prospective study reports on the dynamics of patient reported QoL and symptoms 
during the acute phase of treatment among 138 locally advanced cervical cancer pa-
tients, treated in an image-guided online adaptive external beam radiotherapy PotD 
protocol. By collecting prospectively weekly questionnaires, a total overview of patient-
reported QoL and symptoms during treatment could be given filling a gap in current 
literature on this topic. Other studies also reported on QoL of cervical cancer patients, 
but to our knowledge this study is the first to report in detail QoL during the acute 
phase of treatment and for adaptive EBRT. During treatment symptoms were moderate 
to largely increased, mirrored by a moderate to large decrease in functioning and global 
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Figure 2a. Symptom scales and single-item symptoms (0 – 100) from the EORTC CX-24. Mean ± 95% 
confidence intervals between 0 and 60 are shown.  
 
 
 
 
 
Figure 2a. Symptom scales and single-item symptoms (0 – 100) from the EORTC CX-24. Mean ± 95% con-
fidence intervals between 0 and 60 are shown.
Figure 2b. EORTC CX-24 Sexual functioning and symptoms (0 – 100). Mean ± 95% confidence intervals 
between 0 and 60 are shown.  
 
 
 
 
 
 
 
 
Figure 2b. EORTC CX-24 Sexual functioning and symptoms (0 – 100). Mean ± 95% confidence intervals 
between 0 and 60 are shown.
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health status. This was followed by a rapid recovery to baseline values 3 months after 
treatment. However, several symptoms remained increased during further follow-up, up 
to one year after treatment.
The frequent assessments during and shortly after treatment revealed differences 
in onset and severity of symptoms over time. During the first five weeks of treatment, 
a large increase was observed for bowel cramps, dysuria, irritated/sore vagina, and 
fatigue; a medium increase for diarrhea, nausea/vomiting, appetite loss, fecal leakage, 
difficulties voiding, menopausal symptoms and pain; and a small increase for urinary fre-
quency, appetite loss, tingling/numbness, dyspnea and insomnia. While most symptoms 
gradually increased during each consecutive week to reach a maximum at 5 weeks or 
1 week after treatment, diarrhea and bowel cramps already reached a maximum within 
the first 3 weeks. The high cell turn-over rate of the gastro-intestinal tract explains this 
early response to irradiation, and most of these symptoms are a result of acute cell death 
and damage to the mucosa or epithelial layer (64-66). Most of the mucosal damage is 
repaired during the first four to six weeks after treatment, and this effect is clearly seen 
back in these patients reported symptoms.
Figure 3. Most frequent reported symptoms on single item level. The response rates are shown in 
percentages with the answer categories: not at all, a little, quite bit, very much.  
 
 
  
 
 
 
 
 
Figure 3. Most frequent reported symptoms on single item level. The response rates are shown in percent-
ages with the answer categories: not at all, a little, quite bit, very much.
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Of the symptoms that were increased during treatment, diarrhea, bowel cramps, 
fecal leakage, dysuria, pain, insomnia, menopausal symptoms and tingling/numbness 
remained lightly or moderate elevated up to one year after treatment compared to 
baseline values. In addition, the increase in urinary leakage, and the sexual/vaginal 
symptoms scale (and its items: vaginal dryness, short/ tight vagina and pain during 
intercourse) became clinically relevant 1 to 4 weeks after treatment and remained at 
a moderately increased level throughout the first year after treatment. This indicates 
that most long-term treatment related symptoms are already present during or shortly 
after treatment, linking early to long-term treatment related symptoms. However, the 
etiology of long-term symptoms is different, and is explained by accumulation of fibrosis 
and damage to the microvasculature, leading to atrophic changes and eventually tissue 
or organ dysfunction (67).
Patient functioning returned to baseline values 3 months after treatment and re-
mained at this level (lower than the norm-population) until one year after treatment. 
Exceptions were emotional functioning that remained at baseline level throughout 
the observation period and cognitive functioning which showed a medium decrease 
3 months after treatment. One year after treatment, sexual activity showed a medium 
increase, while sexual worry was medium increased and sexual enjoyment medium de-
creased. Although sexual activity increased from 6 months after treatment, it remained 
lower than the age-matched norm population.
As stated in the Introduction section, other studies have been done to report on QoL 
after treatment for cervical cancer. Most studies are cross sectional and heterogeneous, 
including both early stage patients treated with radical surgery and advanced stages 
treated with definitive radiotherapy, but few report on symptoms and functioning 
during radiotherapy treatment (50-52,54,55). Further, there is no data available of 
comparable studies using adaptive EBRT. Long-term side effects of radiotherapy may 
appear anywhere from months to years after exposure of radiation. It remains dif-
ficult to quantify whether treatment-related morbidities have short and/ or long term 
implications for QoL. Caution in interpretation of all studies remains needed (68,69). 
Furthermore, interpreting results from other QoL studies remains a challenge because 
of diverse patient populations, treatments (mainly 3DCRT) and cultural boundaries. Few 
studies put these results in perspective; Kirchheiner et al. (52) reported on a prospective 
cohort of 50 patients treated with definitive (chemo)radiotherapy and image guided 
adaptive brachytherapy using EORTC QLQ-C30 and CX24 before, during (after external 
beam radiotherapy, comparable to week 5), 1 week and 3 months after treatment. In this 
study, the brachytherapy was started after EBRT. Comparable increase of symptoms and 
decrease of functioning is observed during treatment in this study. In a recent analysis 
from the EMBRACE study (53), QoL was analyzed longitudinally among 744 patients 
treated with definitive (chemo)radiotherapy (74% 3D conformal, 26% IMRT) and image 
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guided brachytherapy. QoL was measured with the EORTC QLQ-C30 and CX24 at base-
line, and at regular intervals from 3 months after treatment until 5 years. Comparing our 
data, functioning scales returned to baseline values after treatment as well. A similar 
increased level of diarrhea, menopausal symptoms and sexual items (vaginal dryness, 
sexual functioning, sexual activity) from 3 months onwards was found. However, in our 
group one year after treatment global health remained stable while role functioning de-
creased, fatigue, body image and sexual worry was one year after treatment increased. 
Park et al. (55) compared the QoL of cervical cancer survivors with a sample of the gen-
eral Korean female population 5 years after radiotherapy. Cervical cancer survivors who 
received radiotherapy reported more impaired social functioning, more constipation, 
diarrhea, urinary symptoms, lymphedema and sexual dysfunction. Furthermore, other 
studies investigating QoL after radiotherapy reported similar persisting symptoms after 
treatment (50,51,54,70).
The comparison with age matched norm population data offers an additional per-
spective to these results. Baseline scores were lower for all functioning scales and higher 
for fatigue, nausea/ vomiting, constipation, appetite loss and financial difficulties in our 
patient group. In contrast, at one year, compared to baseline a small decrease of symp-
toms related to cervical cancer was found for nausea/vomiting, constipation, appetite 
loss, urinary frequency, vaginal discharge and blood loss.
By prospectively collecting questionnaires frequently during and shortly after 
treatment up to one year, a comprehensive overview of the dynamics of QoL during 
treatment could be given, providing useful results for patients and healthcare providers 
on what to expect during and shortly after treatment. Especially direct frequencies of 
response categories (Appendix 5B) provide easily interpretable data that may be use-
ful during counseling. The comparison with the age-matched norm population data, 
using validated questionnaires, contributes to this. Though, the heterogeneity in use 
of chemo- and hyperthermia in this study introduced a certain limitation. Therefore, in 
an exploratory analysis of the impact of different patient and treatment characteristics 
on the most significant single-items; diarrhea and dysuria (Appendix 5C) did not reveal 
any prognostic factor. The lack of difference between movers and non-movers could be 
interpreted as a benefit of the PotD approach. However, in our opinion the subgroups 
were too small and heterogeneous, with corresponding broad confidence intervals, to 
clearly state if any of these characteristics had a significant impact on the outcome of 
QoL.
In this study, we reported our QoL results after six months and one year follow up 
in order to make it easier for the reader to position our results of the acute phase with 
the QoL results reported of the late phase. A limitation of that data is the response rate 
that dropped to 30%. The main cause was withdrawal from participation. Currently, 
we are implementing measures to increase the response rate for long-term follow up. 
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The results of long-term follow up will be reported in a future publication. To that end, 
prospective QoL collection is continued up to five years after treatment.
Continued development of technology can be expected in the future enabling further 
dose reductions to organs at risk. In this study a modern radiotherapy technique was 
used using small margins. Examples include improvements in the PotD strategies, 
in-room MRI-guidance, improvements in treatment plan generation and the use of 
proton therapy. Further progress in brachytherapy and systematic therapy may also be 
expected. The data provided in this study, especially during and shortly after treatment, 
could be used as reference to establish the efficacy of the new approaches in terms of 
patient-reported QoL. For EBRT, baseline and end of EBRT (week 5) are most sensitive 
to measure the impact of short treatment related toxicity and to compare improved or 
reduced symptom burden and QoL.
In conclusion, treatment has a profound impact on QoL, temporarily affecting func-
tioning, but some symptoms persist and impact during further follow-up. End of exter-
nal beam treatment is the most sensitive time point to measure future improvements 
in IGART.
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AbSTRACT 
background & purpose
Library-of-plans ART is used to manage daily anatomy changes in locally advanced 
cervical cancer. In our institute, the library contains 2 VMAT plans for patients with large 
cervix-uterus motion. Increasing this number could be beneficial for tissue sparing, but 
is burdensome while the dosimetric gain is yet unclear. This study’s aim is to determine 
the optimal number of plans at an individual patient level.
Material and Methods
Data of 14 treated patients were analyzed. Plan libraries were created containing 1-4 
VMAT plans. Pre-treatment extent of uterus motion was defined by the Hausdorff dis-
tance (HD). For dosimetric evaluations, OARs were contoured in daily CBCT scans, plan 
selection was simulated, and the V45Gy and V40Gy parameters were recorded.
Results
Moderate to strong correlations were found between HD and the volume of spared OARs. 
All patients benefitted from adding a 2nd plan, as is the clinical practice. For patients with 
a HD between 30 and 50 mm, a 3-plan library reduced the composite V40Gy with 11 ml to 
21 ml compared to a 2-plan library.
Conclusion
Patients with large uterus motion (HD > 30 mm) would benefit from an extension of 
the plan library to 3. HD is an easy-to-implement criteria to select those patients pre-
treatment.
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inTRoDuCTion
Cervical cancer is one of the most common female malignancies worldwide. Radio-
therapy is the major treatment modality for locally advanced disease, combined with 
either chemotherapy or hyperthermia. Although radiotherapy have been improved with 
the introduction of Intensity Modulated Radiotherapy (IMRT) or Volumetric Arc Therapy 
(VMAT), the combined treatment is still associated with toxicity (44,55,56).
Since 2011, more than 200 locally advanced cervical cancer patients have been treated 
with an online adaptive Plan-of-the-Day (PotD) protocol in our institute. In this protocol, 
each patient has an individualized plan library containing either one or two treatment 
plans. The library is supplemented with a backup plan in case the observed anatomy 
does not fit the plans in the library or the protocol cannot be executed. A daily acquired 
Cone Beam CT (CBCT) scan is used to select the plan that best fits the anatomy of the 
day (25).
To generate the treatment plan library, each patient receives an empty and full blad-
der CT scan. These are used to generate model-predicted Internal Target Volumes (ITVs) 
that are used as input for the library of treatment plans. For patients with a tip-of-uterus 
displacement larger than 2.5 cm (measured in the full and empty bladder CT scan), the 
library contains two VMAT plans, for ITVs related to an empty-to-half-full bladder, and a 
half-full-to-full bladder, respectively (25). For patients with smaller motion, the library 
contains one VMAT plan.
Main goal of the protocol is to reduce the dose to healthy surrounding tissues. A 
recent prospective analysis of the patient reported Quality of Life (QoL) performed in 
our institute showed that bowel and bladder side effects gradually increase during the 
first weeks of treatment reaching the highest level in the 5th week (71). These results 
motivate to further improve the current PotD procedure. The hypothesis is that with an 
increasing number of plans healthy tissues are better spared thereby potentially reduc-
ing treatment-related side effects. However, the number of library plans for a patient has 
to be carefully considered, because of the increased workload associated with creating 
multiple treatment plans per patient. Moreover, more plans and consequently smaller 
ITVs may also impact target coverage, as there is less room in the ITVs to accommodate 
deviations from the pre-treatment established motion model. In this study, we evalu-
ated target coverage and OAR dose for plan libraries containing 1-4 VMAT plans. We 
also developed an easy-to-use metric to determine the optimal number of plans at an 
individual patient level.
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MATeRiALS AnD MeTHoDS
Fourteen locally advanced cervical cancer patients that were treated in our center with 
the PotD protocol were analyzed. Patients included in this study had large tip-of-uterus 
displacement (>2.5 cm) as observed between the empty and full bladder CT scan. The 
displacement was manually measured after fusing the empty and full bladder CT scan 
using the bony anatomy. Approximately 30% of all cervical cancer patients had a motion 
of more than 2.5 cm.
Table 1a. Patient overview and characteristics.
Patient Age FiGo stage Position Further treatment
1 37 IIB Prone Chemoradiation
2 34 IVA Prone Neoadjuvant chemotherapy followed by radiotherapy and hyperthermia
3 30 IIB Prone Neoadjuvant chemotherapy followed by radiotherapy and hyperthermia
4 51 IIB Prone Neoadjuvant chemotherapy followed by radiotherapy and hyperthermia
5 40 IB2 Prone Chemoradiation
6 43 IIB Prone Neoadjuvant chemotherapy followed by radiotherapy and hyperthermia
7 43 IB2 Prone Chemoradiation
8 50 IB1 Prone Chemoradiation
9 41 IIB Prone Chemoradiation
10 32 IB2 Prone Chemoradiation
11 44 IIB Prone Chemoradiation
12 43 IB2 Prone Chemoradiation
13 41 IIB Prone Chemoradiation
14 44 IIB Prone Neoadjuvant chemotherapy followed by radiotherapy and hyperthermia
Table 1b. Overview of plan libraries created for all patients.
Plan library Set of plans 
1-plan library 1. empty-to-full-bladder plan 
2-plan library 1. empty-1/2 bladder plan 
2. 1/2-full bladder plan 
3-plan library 1. empty-1/3 bladder plan 
2. 1/3-2/3 bladder plan
3. 2/3-full bladder plan 
4-plan library 1. empty-1/4 bladder plan 
2. 1/4-1/2 bladder plan 
3. 1/2-3/4 bladder plan
4. 3/4-full bladder plan 
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Patient characteristics and treatment variables can be found in Table 1a. To model each 
patient’s bladder filling and impact on cervix-uterus motion, a full and empty bladder 
CT scan was acquired pre-treatment with the patient in treatment position. A drinking 
protocol was used to obtain a sufficiently filled bladder for the full bladder CT scan and 
for each treatment fraction (25). In the drinking protocol patients were asked to drink 
300 ml of water two hours prior to scanning or treatment and to empty the bladder and 
drink an additional 300 ml of water one hour later. Patients were treated in prone posi-
tion. Implanted fiducial markers are used to daily verify the position of the target (72).
Plan Library Generation
For each patient, the delineated cervix-uterus surface in the full-bladder planning CT 
scan was non-rigidly registered to the cervix-uterus in the empty-bladder CT scan (5,31). 
Patient specific motion-models were created by fitting the coordinates of registered 
points on cervix-uterus surfaces with linear functions of bladder volume (15). These 
motion-models were used to generate model-based ITVs, which account for the cervix-
uterus motion due to bladder volume variations.
For this study, four plan libraries were created per patient. The libraries contained 1, 2, 
3, or 4 treatment plans, based on ITVs covering the full cervix-uterus motion sub-ranges. 
Figure 1 shows these ITVs for one of the patients. Each of these ITVs was extended with 
a 10 mm PTV margin, which is also used in current clinical practice. To establish full PTVs, 
the cervix-uterus PTVs were combined with the nodal CTV, extended with a 7 mm PTV 
margin. Table 1b provides an overview of the generated plan libraries. Two cases in our 
study, where mostly full, or empty plans were selected are patients 7 and 14 (Fig. 2). 
Introducing a 2nd plan to the library for the patient with mostly full plans (P7) reduced 
significantly V40Gy of the bladder (17 ml), compared to the limited reduction of the bowel 
cavity V40Gy (2.3 ml). For the patient with mostly empty plans selected (P14), reduction 
of V40Gy for the bladder was relatively small (7 ml), but high for the bowel cavity (33 ml).
Treatment Planning
For all PTVs, VMAT plans were created to deliver 95% or more of the prescribed dose 
to a minimum of 99.5% of the PTV, while no more than 0.2% of the PTV should receive 
more than 110% of the prescribed dose. The prescribed dose was 46 Gy delivered in 23 
fractions of 2 Gy per fraction [4]. Treatment plans were generated using our in-house 
developed optimizer for fully automated multi-criterial optimization (Erasmus-iCycle) 
(20). The optimizer was used for fluence profile optimization using a fixed beam arrange-
ment of 20 equi-angular beams mimicking VMAT (29). Plan optimization was based on 
an a-priori defined “wish-list” with hard constraints, and prioritized objectives. Sparing 
of small bowel had a higher priority than reducing delivered dose to the rectum and 
bladder. The cervical cancer wish-list as used in this study has been reported in (29,73).
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Treatment Simulation and Dosimetric Evaluation
For the dosimetric simulations, the cervix-uterus and the bladder, rectum and bowel 
cavity were delineated in each daily CBCT scan by a single investigator according to 
the RTOG guidelines (39,40). Contours were reviewed by an experienced radiation 
oncologist. The bladder and rectum were contoured as solid organs. The bowel cavity 
was defi ned as all loops of small bowel, colon, including peritoneal space between the 
loops. Each CBCT scan was registered to the planning CT scan using a rigid bone match 
(as performed during actual treatment). Similar to clinical practice, plans were selected 
based on the bladder volumes in the daily CBCT scans, (13). Coverage was assessed by 
calculating the daily V95 (%), i.e. the volume receiving at least 95% of the prescribed daily 
dose.
For each plan library, the V45Gy (ml) and V40Gy (ml) for the bowel cavity, V40Gy (ml) for 
the rectum, and V40Gy (ml) for the bladder were calculated from the daily dose volume 
histogram (DVH). DVH parameters were analyzed for each fraction separately, as dose 
warping based on deformable image registration can still lead to incorrect dose distri-
butions in the pelvic region (74). In particular, the bowel cavity is a large structure, which 
exhibits sometimes large and local deformations. To summarize the fi ndings, median 
DVH parameters over all fractions were calculated for each patient.
The following analyses were performed based on the simulated PotD treatments:
1. We assessed target coverage of the cervix-uterus and OAR sparing by comparing 
the recorded DVH parameters of the 1-plan library to the 2-plan, 3-plan, and 4-plan 
library.
2. We developed an easy-to-use metric to determine the optimal number of plans for 
each patient based on the pre-treatment CT scans. To that end, we evaluated the 
Pearson correlation between the DVH parameters of the diff erent plan libraries and 
Figure 1. ITVs constructed for a single patient from the full and empty bladder pre-treatment CT 
scans. ITV ranges: A: an empty-full bladder (green). B: an empty-1/2 bladder (green), 1/2-full bladder 
(blue). C: an empty-1/3 bladder (green), 1/3-2/3 bladder (blue), 2/3-full bladder (red). D: an empty-
1/4 bladder (green), 1/4-1/2 bladder (blue), 1/2-3/4 bladder (red), 3/4-full bladder (yellow). 
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scans. ITV ranges: A: an empty-full bladder (green). B: an empty-1/2 bladder (green), 1/2-full bladder 
(blue). C: an empty-1/3 bladder (green), 1/3-2/3 bladder (blue), 2/3-full bladder (red). D: an empty-
1/4 bladder (green), 1/4-1/2 bladder (blue), 1/2-3/4 bladder (red), 3/4-full bladder (yellow). 
 
 
 
Figure 1. ITVs constructed for a single patient from the full and empty bladder pre-treatment CT scans. 
ITV ranges: A: an empty-full bladder (green). B: an empty-1/2 bladder (green), 1/2-full bladder (blue). C: an 
empty-1/3 bladder (green), 1/3-2/3 bladder (blue), 2/3-full bladder (red). D: an empty-1/4 bladder (green), 
1/4-1/2 bladder (blue), 1/2-3/4 bladder (red), 3/4-full bladder (yellow).
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the extent of cervix-uterus motion observed between the full and empty bladder CT 
scan. The extent was quantifi ed as the Hausdorff  distance (HD). To calculate the HD, 
we determined the minimal distances between all corresponding surface points of 
the cervix-uterus in the full and empty bladder CT scan. The HD is defi ned as the 
largest minimal distance of all surface points. To eliminate the eff ect of delineation 
outliers, we took the 99-percentile HD, which we denote as HD in this manuscript.
3. To assess the global benefi t of plan-library expansion for all surrounding healthy 
tissues, we calculated a composite DVH parameter (the composite V40Gy) for each pa-
tient by summing up the DVH parameters of the bowel cavity, bladder, and rectum.
A Wilcoxon signed-rank test was used to assess statistical diff erences among strategies. 
Statistical analyses were performed using SPSS Statistics version 21 (IBM, Armonk, NY, 
USA) and p-values < 0.05 were considered statistically signifi cant.
Figure 2. Bar chart of the selected plans for each patient for the 3-plan library and 4-plan library 
approach. Data are expressed as percentages. 
 
 
 
 
 
Figure 2. Bar chart of the selected plans for each patient for the 3-plan library and 4-plan library approach. 
Data are expressed as percentages.
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ReSuLTS
Plan Selection and Target Coverage 
Consistent with earlier fi ndings, bladder volume decreased during treatment, with 
median bladder volumes of 208 ± 44 ml, 183 ± 23 ml, 154 ± 25 ml, and 153 ± 4 ml 
during the 1st, 2nd, 3rd, and 4th treatment quarter, respectively. This is refl ected in the plan 
selection. During the second half of the treatment, empty bladder plans were selected 
20% more often and full plans 11% less often compared to the fi rst half of the treatment. 
Intermediate plans were selected 10% more often during the fi rst half of the treatment. 
Figure 2 shows the distribution of selected plans for each patient for a 3-plan and 4-plan 
library.
Two patients (P1, P4) were identifi ed as outliers. Patient (P1) had 39% of the fractions 
an emptier bladder than on the empty-bladder CT scan taken prior to treatment. Patient 
(P4) had 65% of the fractions a fuller bladder than on the full planning CT scan. In these 
cases, model-predicted ITVs derived from the empty and full bladder planning CT scans 
were not correct for those fractions and the data do not follow the pattern of the ob-
servations for other patients. Data of these two patients were therefore excluded from 
further analysis. In clinical practice, such cases would receive new treatment planning 
CT scans with full and empty bladder and a new library would be created.
The V95 of the cervix-uterus was ≥ 99.5% for 318 (99%), 316 (98%), 314 (97.5%) and 313 
(97%) of the fractions for the 1-plan, 2-plan, 3-plan and 4-plan library, respectively (Fig. 
3). The V95 was below 99.5% for 2 patients in 3 fractions for the 1-plan and 2-plan library, 
and in 4 fractions for the 3-plan and 4-plan library. The V95 for each patient and each plan 
library was plotted in Appendix 6A.
 
Figure 3. Box plot of the cervix-uterus V95 for all patients and individual approaches. The boxes are the 
first a d third quartiles, with media  s the horizontal line inside the box. Upper and lower limits are 
the 95 and 5 ercentiles. 
 
 
Figure 3. Box plot of the cervix-uterus V95 for all 
patients and individual approaches. The boxes 
are the fi rst and third quartiles, with median as 
the horizontal line inside the box. Upper and 
lower limits are the 95 and 5 percentiles.
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Figure 4. Differences in the average DVH parameters for bowel cavity, bladder and rectum for 
different plan library approaches, for each patient. The data is presented relative to the 1-plan library. 
The patients are sorted in increasing order of HD.  
 
 
Figure 4. Diff erences in the average DVH parameters for bowel cavity, bladder and rectum for diff erent 
plan library approaches, for each patient. The data is presented relative to the 1-plan library. The patients 
are sorted in increasing order of HD.
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oAR sparing
The dosimetric eff ect on the OARs of increasing the number of library plans is shown in 
Fig. 4 for each patient. The median bowel cavity volume V45Gy averaged over all patients 
was reduced by 17.3 ml (range 50 to 0.1 ml), 23.6 ml (range 67 to 0 ml), and 26 ml (range 
73 to 0.1 ml) comparing 2, 3, and 4-plan libraries to a 1-plan library, respectively. All 
diff erences were statistically signifi cant with p=0.001.
The median bladder volume V40Gy averaged over all patients was reduced by 14 
ml (range 49.0 to 1.3 ml), 20.0 ml (range 60 to 1.7 ml), and 23 ml (range 67 to 0.5 ml) 
comparing 2, 3, and 4-plan libraries to a 1-plan library, respectively. All diff erences were 
statistically signifi cant with p=0.001.
The median rectum volume V40Gy averaged over all patients was reduced by 4.0 ml 
(range 9 to 0.8 ml), 5.5 ml (range 12 to 1 ml), and 6 ml (range 13 to 0.8) ml) comparing 
2, 3 and 4-plan libraries to a 1-plan library, receptively. All diff erences were statistically 
signifi cant with p=0.001.
A moderate correlation was found between patient pre-treatment extent of uterus 
motion (HD) and a reduction in V45Gy of the bowel cavity (R=0.71, 0.73, and 0.77 for 2, 
3, and 4-plan libraries compared to an 1-plan library, respectively). There was not a 
signifi cant correlation found between pre-treatment extent of uterus motion (HD) and 
reductions in bladder V40Gy or rectum V40Gy.
In order to evaluate the global benefi t of library expansion for each patient, we also 
calculated a composite volume by summing up the DVH parameters for the bowel cav-
Figure 5.  
Linear regression analysis plots. Overall gain of V40Gy for bowel, bladder and rectum by adding 2nd 
(blue), 3rd (red) or 4th plan (green) to the plan library compared with a 1-plan library. The data is 
correlated with the HD of the cervix-uterus. R = Pearson correlation coefficient. Observations of two 
patients were identified as outliers and were excluded from this analysis. More detailed explanation 
of the cause of the outliers can be found in the text. 
 
 
 Figure 5. Linear regression analysis plots. Overall gain of V40Gy for bowel, bladder and rectum by adding 2
nd 
(blue), 3rd (red) or 4th plan (green) to the plan library compared with a 1-plan library. The data is correlated 
with the HD of the cervix-uterus. R = Pearson correlation coeffi  cient. Observations of two patients were 
identifi ed as outliers and were excluded from this analysis. More detailed explanation of the cause of the 
outliers can be found in the text.
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ity, bladder, and rectum for each patient. This composite parameter was also related to 
the pre-treatment extent of uterus motion (HD).
Figure 5 shows the reduction in V40Gy comparing a 2, 3, or 4-plan library to a 1-plan 
library. Considering that a reduction in the composite V40Gy of more than 10 ml justifies 
the addition of a plan to the library, the linear fit to the 2-plan vs. 1-plan data shows 
that patients with a HD>20 mm benefit from adding a 2nd plan to library. This resembles 
current clinical practice. The linear fits to the data also show that for patients with a HD 
between 30 and 50 mm a 3-plan library could be recommended reducing the composite 
V40Gy with 11 ml to 21 ml compared to a 2-plan library and with 36 ml to 71 ml compared 
to a 1-plan library. For patients with a HD>50 mm a 4-plan library could be considered 
reducing the V40Gy with at least 9, 30, and 80 ml compared to a 3, 2, and 1-plan library, 
respectively.
DiSCuSSion
In this study we performed a dosimetric analysis to investigate the benefits of increas-
ing the number of library plans in Plan-of-the-Day adaptive radiotherapy in locally 
advanced cervical cancer. A strong correlation was found between the pre-treatment 
extent of uterus motion (HD) and the reduction in composite V40Gy of the 2, 3, and 4-plan 
libraries compared to a 1-plan library. Therefore, this metric can be used to determine, 
pre-treatment, the number of library plans at an individual patient level.
Our results show that patients with a HD>20 mm benefitted from the 2-plan library 
compared to a 1-plan library, resembling current practice. Patients with large uterus 
motion (HD>30 mm) would have benefitted from adding a 3rd plan to the library. Here, 
we considered that a reduction in the composite V40Gy of more than 10 ml justifies the 
addition of a plan to the library. Patients with extremely large motion (HD>50 mm) 
could benefit from adding a 4th plan to the plan library, though the reduction in V40Gy is 
modest by adding a 4th plan to the 3-plan library. All strategies resulted in acceptable 
target coverage.
We found that an extension of the plan library for patients with large cervix-uterus 
motion is most beneficial for the bowel cavity. The gain in bladder sparing was moderate 
and the gain in rectum small. Most complications after radiotherapy for cervical cancer 
originate from the dose to the bowel cavity (44,48,56) and we consider this as the most 
important OAR. Therefore, we hypothesize that the use of more plans in the library leads 
to a reduction in bowel toxicity rates and improved patient symptoms and QoL. Future 
research has to confirm this hypothesis.
The gain in bowel and bladder sparing depended on the volume of the bladder in the 
daily treatment fractions. The bladder volume affected the dose received by the bowel 
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cavity. This can be explained by the fact that a full bladder pushes the bowel upward 
thus out of the irradiated volume (75,76). We also observed that in this case the V40Gy of 
the bladder increased. This exchange in sparing between bowel cavity and bladder was 
the reason to calculate a composite metric to assess the global benefit of expanding the 
plan library. The composite metric, however, is difficult to relate to a specific symptom.
In our population, we observed large bladder filling variations and a gradual reduc-
tion in bladder volume despite the use of a drinking protocol aiming for a full bladder. 
This finding is consistent with published data (10,77,78). The decrease of the bladder 
volume with time can be explained by increasing radiation cystitis as well as inadequate 
hydration secondary to diarrhea and nausea (77).
A recent study of van de Schoot et al. (78) quantified the potential dosimetric benefits 
of a daily adaptive plan selection strategy compared with a non-adaptive treatment 
approach in cervical cancer. They found significant improvements in target coverage 
when applying adaptive radiotherapy in line with Heijkoop et al. (25). A significant 
reduction in dose to bowel and rectum was observed as well. The study, however, did 
not address the optimal number of plans in a plan library. A study of Seppenwoolde et 
al. (79) confirmed better dosimetric results for a 2-plan library approach compared to a 
margin concept for cervical cancer patients. However, the main conclusion was that the 
ITVs based on the planning CT scan could change during the course of treatment and 
that therefore adapted ITV margins based on a repetitive motion evaluation in the first 
week of treatment could provide improvements over the static margin concept. In our 
study, we introduced an objective metric to individualize the number of plans in the 
library. With this metric, the consideration between OAR sparing and workload can be 
made prior to treatment planning (80-83).
Future improvements could be achieved by reducing the CTV-to-PTV margin around 
the nodal CTV and the model-predicted ITVs. However, careful monitoring of the posi-
tion of the target volumes will be mandatory in order to avoid any geometrical misses. 
This should be combined with efficient updates of the plan library in case the plan library 
is not representative anymore for the current anatomy of the patient.
There are limitations in this simulation study. DVH parameters were analyzed for each 
fraction separately, as dose warping based on deformable image registration can still 
lead to incorrect dose distributions in the pelvic region (74). In particular, the bowel 
cavity is a large structure, which exhibits sometimes large and local deformations. The 
bladder and rectum were contoured as solid organs, which is not fully representative for 
their actual shape (84). However, contouring the walls in the CBCT scans would be very 
challenging and prone to observer variation.
In conclusion, our dosimetric simulation study demonstrated that patients with large 
bladder-induced motion of the cervix-uterus benefit from expanding the plan library 
from 2 to 3 or 4 treatment plans. Furthermore, we introduced and tested an objective 
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metric that can be used to choose, pre-treatment, the number of plans on an individual 
patient level. This metric is the 99-percentile of the Hausdorff distance between the 
cervix-uterus surface points in a full and empty bladder CT scan (HD). For patients with 
moderate to large uterus motion (20 mm ≥ HD > 30 mm) we recommend a 2-plan library, 
for patients with large cervix-uterus motion (HD > 30 mm) we recommend a 3-plan li-
brary, and for patients with extremely large motion (HD > 50 mm) a 4-plan library could 
be considered.
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7.1 inTRoDuCTion
This thesis focuses on an online adaptive approach for EBRT in locally advanced cervi-
cal cancer patients, based on patient-specific plan libraries that are used in a so-called 
Plan-of-the-Day (PotD) strategy. The aim was to evaluate and optimize this adaptive ap-
proach, and to investigate important factors having an impact on daily clinical practice.
7.2 iMPRoveMenT oF PATienT TReATMenT
After the preliminary research by Ahmad et al. and Bondar et al. (9,15), the PotD adaptive 
approach for cervical cancer patients was introduced in our clinic in June 2011 (Chapter 
2). Until February 2017 more than 200 patients were treated with the PotD protocol. 
Since the implementation, various steps have been taken to optimize the protocol, 
which will be discussed in this section.
Quality of the plan library
For the first patients, the library plans were sometimes not optimally suitable for treat-
ment. One of the causes was that the CT-scans acquired during planning did not include 
a scan with a really empty or a really full bladder. In current clinical practice, the acquired 
scans are immediately checked for this by visual inspection. It was furthermore observed 
that for some patients, the rectum filling in the planning CT scans differed substantially 
from the filling in the daily CBCT scans. To improve this, in May 2014 we started to use 
rectum laxatives for all patients, prior to acquisition of the planning CT scan, to have a 
more representative rectum filling for EBRT.
Daily plan selection
Initially, the patient’s PTV structure was displayed on the matched CBCT scan for daily 
plan selection. In September 2014, it was decided to replace the PTV by the 95% isodose 
line, as it will result in sufficient coverage with less necessity for selection of the backup 
plan.
In the second phase of implementation, the group of patients with large cervix-uterus 
motion (‘movers’) initially received a post-treatment CBCT to ensure that the correct 
treatment plan was selected, given potential bladder filling during treatment and 
thereby intra-fraction motion. Based on the findings in Chapter 3 and the transition to 
VMAT, the post CBCT scan has been discarded from the protocol since April 2015.
Chapter 7 
96
vaginal catheter
Initially, a vaginal catheter was used for verification of the cervix position in the planning 
CT scan. However, Langerak et al. (72) showed that the vaginal catheter resulted in a 
mean displacement of the markers implanted in the vaginal fornices of 1.3 mm in the 
caudal direction, as compared to the first CBCT scan where no catheter was used. Cur-
rently, the use of a vaginal catheter is no longer needed because planning CT-scans are 
matched with an MRI scan. In june 2016, the use of vaginal catheters was stopped. It will 
be evaluated wheter less backup plans will be selected.
Quality of Life questionnaires
Since December 2011, Quality of Life (QoL) questionnaires have been collected to inves-
tigate the dynamics of patient reported symptoms and QoL during the acute phase of 
treatment until one year (Chapter 5). However, we observed high response rates at the 
beginning of treatment with a drop after some months. The response rate after one year 
of treatment was only 39%. Some patients didn’t reach this follow-up point, but most pa-
tients stopped responding despite intensive contact by email, phone and the outpatient 
clinic. In the last few years, the response rate has improved due to sending automatically 
generated emails to patients including the questionnaires next to using paper forms. The 
younger patient cohort showed an increased response rate due to the digitalization, but 
for the older patients an improvement was not seen. To further improve response rates, es-
pecially for older patients, a new digital application will be created for the outpatient clinic. 
Patients will be asked by their own radiation oncologist to fill out the digital questionnaire 
on site, just prior to the regular follow-up visits. The outcome of the questionnaire will then 
be discussed immediately during the follow-up visit (fig 1).
Figure 1. Example of patient reported symptoms using the EORTC QLQ-C30 questionnaire. Lower 
scores point at better QoL. Measurements at different time points are shown. [Pat] refers to patient. 
 
 
Figure 1. Example of patient reported symptoms using the EORTC QLQ-C30 questionnaire. Lower scores 
point at better QoL. Measurements at different time points are shown. [Pat] refers to patient.
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Plan-of-the-Day functionality in the Linear Accelerator (linac) Record & verify 
system 
Initially, our record and verify system, Mosaiq (version 2.3, Elekta AB, Stockholm), did not 
support online adaptive PotD strategies (Chapter 2). All library plans were enabled at 
each treatment day, from which only one was selected and executed. To reduce the risk 
of double or triple exposure, the one or two “other” plans had to be manually removed 
immediately after treatment delivery. Accumulated dose was not recorded for the PotD 
approach, so delivery of the correct number of fractions was not guaranteed by the 
system. Although in that time the protocol contained some minor errors, delivery errors 
did never occur. However, to enhance safety, Erasmus MC and Elekta collaborated on the 
development of a dedicated feature in Mosaiq for safe and effi  cient application of PotD 
protocols (85), which was implemented in Mosaiq version 2.5 (fi g 2). A straightforward 
plan selection dialog is presented to the RTTs, which immediately disables the unchosen 
plans, thereby eliminating the risk of excessive dose delivery. Moreover, the total dose 
is now correctly registered to avoid delivery of an erroneous number of treatment frac-
tions. The feature was implemented in our clinic in October 2014.
Figure 2. Example of a treatment dialog for a mover (3 plans available in the plan library).  
 
 
 
 
 
Figure 2. Example of a treatment dialog for a mover (3 plans available in the plan library).
vMAT only – no 3DCRT, no iMRT
In October 2014, the applied IMRT technique was replaced by VMAT. The use of VMAT 
led to a major reduction in treatment time from 12 minutes to 4.8 minutes. The applied 
VMAT plans are fully automatically generated (29,73). The quality of these plans is su-
perior to manually generated plans (29). Since March 2015, the motion robust backup 
plan is also delivered with VMAT, instead of the previously used 3DCRT. This VMAT plan 
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has generous margins (2 cm around the Internal Target Volume (ITV) and 1 cm around 
the lymph nodes). As all plans are now VMAT, the treatment time in all fractions is ap-
proximately the same, which has logistic advantages.
Prone instead of supine treatment
In Chapters 2 and 3, all results were obtained for patients treated in the prone position 
using a bellyboard. The choice for the prone treatment position was based on an in-house 
study from Olofsen-van Acht et al. for 3DCRT treatment (9). However, a disadvantage of 
using a bellyboard is reduced CBCT image quality, on top of occurrence of rotations (42) 
and discomfort for the patients. Because of these disadvantages and the need to match 
the planning CT scan with MRI, the question emerged whether the historical advantage 
for the prone position was also valid for complex IMRT/ VMAT techniques and adaptive 
approaches. As a result of the study reported in Chapter 4, since June 2016, all patients 
are treated in supine setup. Having a more stable position in supine, the nodal margin 
could also be reduced from 10 mm to 7 mm.
7.3 TowARDS FuTuRe CLiniCAL iMPLeMenTATionS AnD STuDieS
In Chapter 6, the patient-specific optimal number of library plans was investigated for 
patients with large cervix-uterus motion (‘movers’). In case of a tip of uterus motion >30 
mm, adding a 3rd tight-margin VMAT plan to the library showed reduced OAR dose, and 
for motion >50 mm, a 4th plan could be considered for further reduction. Due to the au-
tomated plan generation (above), extra plans can be generated with no extra planning 
workload. However, it must be considered that the workload for the RTTs at the linac 
may rise drastically. In the current version of the XVI software (version 5.0, Elekta AB) all 
structures are displayed in a drop-down menu, when the CBCT scan is matched to the 
planning CT scan. For the current approach with 2 tight-margin plans in the library for all 
movers, the drop-down menu list already shows many options to choose from. Adding 
more plans to the library automatically leads to an enhanced number of options. This 
will lead to an increased workload because the RTTs need to consider which treatment 
plan best fits the observed anatomy for that day. Also, having more options could lead 
to an increased fault percentage. Input from specialized RTTs learned that currently a 
total of 4 plans in the library is the maximum feasible, considering daily workload with 
the current software, which should be adapted before clinical introduction of libraries 
with > 4 plans. Fortunately, the majority of patients treated is non-mover with only one 
tight-margin VMAT plan in the library. For this group, the workload is low. Extremely 
large motion, requiring 4 tight margin library plans, is expected to occur in our clinic at a 
maximum 3 times a year. Therefore, this will not affect the overall workload significantly. 
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Development of daily automatic plan selection could potentially solve both problems of 
the workload and plan selection errors. As a result of this study, for some patients with 
very large motion, plan libraries will be expanded in the near future. 
Our department will participate in the EMBRACE II study. Compared to the current 
PotD protocol, treatment planning will have to be adapted as different constraints are 
set on PTV coverage (86). With the introduction of this protocol, our margins will also 
be adapted, for the cervix-uterus ITV-to-PTV from 10 mm to 5 mm, and for the nodal 
CTV-to-PTV from 7 mm to 5 mm (86). Further, underdose of the tip of the uterus is al-
lowed. The applied margin reductions could result in more frequent selection of motion 
backup plans, which could possibly counteract advantages of the margin reductions. 
On the other hand, the allowed underdose in the tip of the uterus could lead to reduced 
selection of backup plans. The margin reductions could potentially negatively impact 
the loco-regional control rate, which needs to be monitored closely.
7.4 CLiniCAL eviDenCe FoR THe PLAn-oF-THe-DAy APPRoACH
PotD involves treatment with tailored, patient-specific PTV margins. For movers, the 
daily used IMRT/ VMAT plan depends on the actual position and shape of the target. 
Using a personalized approach, OAR dose delivery is kept minimal for every patient. For 
movers with very large cervix-uterus motion, PotD may also limit underdose compared 
to conventional treatment with one IMRT/VMAT plan with population-based margins.
So far, no clinical evidence has been gathered proving superiority of the PotD approach 
compared to conventional treatment. Such evidence is desired as PotD has higher execu-
tional costs than conventional treatment. Conducting a randomized clinical trial may be 
challenging because of the problematic weighting of a likely reduction in toxicity with 
some increase in cost. In the Netherlands, randomized clinical trials comparing proton 
therapy with photon therapy are largely avoided in case of expected toxicity reduction. 
Instead, the so-called model-based approach is followed (87). In principle, this could 
also be done for PotD. However, the highly patient-specific variations in bladder filling 
with resulting mobility of the target, and the lack of toxicity prediction models make this 
approach challenging. In the international, prospective EMBRACE II study, participating 
centers are allowed to use different strategies for the EBRT part of the treatment. Centers 
with basic IGRT (standard population based margins), intermediate IGRT (individualized 
margins), and advanced IGRT (PotD with individualized patient libraries) can all par-
ticipate. QoL and toxicity will be scored in a consistent way at several time points. This 
data could be used to compare conventional EBRT with PotD approaches to assess to 
presumed clinical advantage of the latter.
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7.5 younG PATienTS - ovARiAn FunCTion & RADiATion THeRAPy
For the patients analyzed in Chapter 5, the median age at diagnosis was 52 years (range 
27 – 86). For young women who have not yet reproduced at the time of treatment, spar-
ing of the ovaries may be of major importance (88). In order to preserve the ovaries in 
these young patients, cryopreservation of ovarian tissue or transposition of the ovaries 
prior to radiation therapy are options (89,90).
In 2015, we observed for 4 patients that despite ovarian transposition, the total func-
tion of the ovaria was lost 6 months after treatment. For two patients, the Dmean was set 
to < 8Gy and for the other two patients the Dmean was < 4Gy. The loss in ovaria function 
may have been caused by the applied radiation dose. Ovarian tissue is highly sensitive 
to radiation (13) and doses ≥4 Gy result in infertility for almost all women over 40 years 
of age, and for one third of the young women (10). Several studies have estimated that 
doses lower than 2 Gy will destroy half of immature oocytes (91,92). On the other hand, 
the applied chemotherapy (cisplatin) also contributes to reduced ovarian function (93), 
although the exact role of chemotherapy on ovarian function has not been defined yet. 
For locally advanced cervical cancer patients, no studies have been performed on the 
interaction and relative importance of the extra role of chemotherapy combined with 
radiotherapy in relation to functioning of the ovaries. Also, a role of the daily imaging 
dose of the CBCT cannot be excluded.
Possibly, better sparing of the ovaries is possible with a modified approach for ovary 
transposition. This needs further research. Another option could possibly be treatment 
with partial arc VMAT, excluding beams passing through the ovaries. Further, in our cur-
rent protocol, the entire uterus is included in the Clinical Target Volume (CTV), because 
uterus and cervix are embryological one unit with interconnected lymphatics and no 
clear separating fascial plane. There is however only little clinical evidence to support 
this approach (41). Recurrence is not expected in the fundus part (94). Because of ana-
tomical proximity of the fundus and the ovaries, excluding the fundus from the target 
volume could possibly allow reduced dose delivery to the ovaries. By decreasing ovary 
doses close to 0 Gy, the role of chemotherapy could be further explored.
Another solution to maintain ovarian function and fertility is ovarian tissue cryopreser-
vation and re-transplantation. It must however be emphasized that for cervical cancer 
patients a gestational carrier is needed. In the Netherlands, cryopreservation is still con-
sidered to be in an experimental phase. For cervical cancer patients, re-transplantation 
of preserved ovarian tissue has not yet been performed.
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7.6 FuTuRe ouTLook
The main goal of the PotD approach for locally advanced cervical cancer has always 
been reduction of dose to OARs and thereby reduction of acute and late toxicity. 
Chapter 5 shows that for bowel and bladder related problems there is still a lot to gain 
in terms of reducing toxicity. Many measures have been taken to improve the current 
PotD approach (above). However, the question rises if the current technique using X-ray 
beams and CBCT based image guidance should still be used for this patient group with 
introduction of new techniques such as in-room MR guidance and proton therapy.
Possibly, a big step forward in the treatment of cervical cancer patients could be the 
use of daily online adaptive replanning. With high quality in-room imaging, uncertainty 
margins could probably be effectively reduced with this approach, which might result 
in lower OAR dose delivery. This needs proper investigation, as even with a zero margin, 
healthy tissues will always be irradiated due to the ballistic properties of the photons 
or particles used. Limited quality of CBCT images is already an important challenge 
for current daily plan selection, and fast and accurate daily contouring by a physician 
or automatic segmentation, as needed for on-line replanning, might even be a bigger 
challenge. Possibly, quality of in-room CT-images may improve with better hard- or 
software. However, most probably, the quality of those images and especially the soft 
tissue contrast will remain inferior to MR-images, especially those provided by future 
integrated MR-linac systems with high magnetic field. (95).
Another question is whether cervical cancer patients could benefit from proton ther-
apy with the upcoming availability of proton therapy in the Netherlands (HollandPTC). 
Intensity Modulated Proton Therapy (IMPT) could result in a decrease of OAR doses, 
enabling dose escalation to the tumor and lymph nodes (96). Especially in terms of small 
bowel and bone marrow sparing, IMPT has a potential for significant dose reductions 
(97,98). As proton therapy is expensive and its capacity low, pre-treatment selection 
of patients with large expected clinical benefit is important. In a recent dosimetric 
comparison using robust proton therapy planning, it was shown that IMPT resulted in 
dose reductions in bowel, bladder, sigmoid, and rectum, without compromising target 
coverage, especially for locally advanced cervical cancer patients with lymph nodes 
in the para-aortic region (99). Another recent study demonstrated that image guided 
proton therapy using a plan library based PotD approach results in a target coverage 
like in photon therapy with significant dose reductions in bladder, bowel and rectum 
(100). In contrast to X-ray treatment units, currently there are no proton therapy systems 
with in-room MR-guidance. The most modern proton systems (like in HollandPTC) will 
be equipped with an in-room diagnostic CT-scanner. Especially the soft-tissue contrast 
of these devices is inferior to that of high magnetic field MR-scanners. Further research 
is needed to investigate the future roles of CBCT guidance at a linac, in-room low [Mrid-
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ian] or high field MR-guidance at a linac, and CT-guidance at a proton facility. For all 
techniques, we need to be aware of the impact of treatment time. An enhanced treat-
ment time requires an enhanced margin to compensate for the increase in intra-fraction 
motion, especially for large movers (Chapter 3).
7.7 ConCLuSion
In this thesis we have described the implementation, evaluation, and optimization of an 
online adaptive Plan-of-the-Day approach in radiotherapy for locally advanced cervical 
cancer. We have demonstrated enhanced OAR sparing with this approach. However, 
clinical evidence for superiority compared to conventional treatment is not yet avail-
able. In the near future, new opportunities (e.g. in-room MR guidance, proton therapy) 
will become available to possibly further reduce OAR doses, potentially improving the 
QoL for this patient group.
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Plan-of-the-Day in the Record and verify System
At present most commercially available record and verify systems do not support online 
adaptive plan of the day strategies. This means that it is not supported to have multiple 
treatment plans enabled, from which only one is selected and executed. In the imple-
mentation of the plan-of-the-day approach reported in this study MOSAIQ version 2.3 
(Elekta AB, Stockholm) was used as record and verify system. In the workflow all avail-
able library plans are imported in advance and scheduled in the treatment calendar. At 
each treatment fraction the operator executes the selected plan. To mitigate the risk of 
double or triple exposure, our protocol prescribes the immediate removal of the one or 
two obsolete plans from the treatment calendar after the delivery of the treatment frac-
tion. The protocol further requires that this procedure is verified by a second operator. 
In the MOSAIQ software the so-called “treatment site” records the executed plan and the 
so-called “secondary dose site” is used to record the total dose delivered.
To reduce workload and enhance safety, the plan selection and administration 
workflow was automated, using the IQ Scripting Engine in MOSAIQ version 2.5 in col-
laboration with Elekta. The scripting allows MOSAIQ users to add new functionality, e.g. 
scripts that define a workflow of configurable activities and that can be executed by 
a user-defined trigger point. The script, exclusively designed for daily plan selection, 
presents to the operator a straightforward plan selection dialog, it immediately disables 
the unchosen plans, and correctly administers the plans and total dose delivered. This 
script will be used for future plan-of-the-day treatments (1).
ReFeRenCeS
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2b
Dosimetric evaluation of the impact of the Plan-of-the-Day Strategy
The potential dosimetric impact of the plan-of-the-day strategy was estimated by evalu-
ating Dose Volume Histogram (DVH) parameters for the relevant organs at risk, i.e. the 
V90% (%) for bladder and rectum, and the V99% (cc) for the bowel cavity (as surrogate 
for small bowel). This evaluation was performed for all 11 patients with two IMRT plans 
(second phase only) and for one representative case with small cervix-uterus motion 
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(one IMRT plan). The dose was evaluated on the full and empty bladder CT-scans as 
during the treatment course both anatomical situations occur. To that end, the rectum, 
bladder, and bowel cavity were contoured in the full and empty bladder CT-scans by a 
single investigator (SH) and carefully checked by an experienced radiation oncologist 
(JM). The empty bladder CT-scans were rigidly aligned to the full bladder CT-scans (the 
planning CT-scan) using the bony anatomy in order to project the dose distributions 
onto the empty bladder CT-scan. Subsequently, DVHs of the 3DCRT backup plan were 
calculated for the full and empty bladder CT-scans. The DVHs of the half-full-to-full IMRT 
plans were calculated for the full bladder CT-scans and the DVHs of the empty-to-half-
full IMRT plans were calculated for the empty bladder CT-scans. For the representative 
case with one IMRT plan the DVHs were calculated for both the full and empty bladder 
CT-scans.
Figures 1(a) to 1(f ) illustrate the potential benefit for patients that were treated with 
two IMRT plans. The figure demonstrates a consistent improved sparing of the OARs in 
favour of the IMRT plans. A pronounced benefit was observed for the bowel cavity when 
the bladder was empty. For the full bladder CT-scan the benefit for bowel cavity was 
less pronounced as a full bladder pushes the bowel partly outside the treated volume 
resulting in overall less bowel being irradiated.
Figure 2 illustrates the potential benefit for a patient with small cervix-uterus motion. 
IMRT yielded a considerable sparing of the OARs compared with the 3DCRT plan. The 
sparing was most pronounced for the bowel cavity in the empty bladder CT-scan. In 
the full bladder CT-scan the advantage for the bowel cavity was less evident as the full 
bladder pushed the small bowel partly outside of the treated volume.
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Figure	  1.	  DVH	  parameters	  for	  the	  IMRT	  plans	  and	  the	  3DCRT	  backup	  plan.	  The	  left	  column	  shows	  the	  
DVH	  parameters	  for	  the	  empty	  bladder	  CT-­‐scan	  and	  the	  right	  column	  shows	  the	  DVH	  parameters	  for	  
the	  full	  bladder	  CT-­‐scan.	  
 
 
 
 
  
Figure 1. DVH parameters for the IMRT plans and the 3DCRT backup plan. The left column shows the DVH 
parameters for the empty bladder CT-scan and the right column shows the DVH parameters for the full 
bladder CT-scan.
Figure	  2.	  DVH	  parameters	  for	  a	  representative	  case	  with	  small	  cervix-­‐uterus	  motion.	  The	  left	  graph	  
shows	  the	  DVH	  parameters	  of	  the	  IMRT	  and	  3DCRT	  plan	  calculated	  on	  the	  empty	  bladder	  CT-­‐scan.	  
The	  right	  graph	  shows	  the	  DVH	  parameters	  for	  the	  full	  bladder	  CT-­‐scan.	  
 
 
 
 
 
 
 
 
 
 
  
  
Figure 2. DVH parameters for a representative case with small cervix-uterus motion. The left graph shows 
the DVH parameters of the IMRT and 3DCRT plan calculated on the empty bladder CT-scan. The right graph 
shows the DVH parameters for the full bladder CT-scan.
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Table 3a. Intra-fraction changes in setup for each patient individually with the mean and the SD in the 
three directions.
Patient motion LR (mm) CC (mm) AP (mm)
# 1 Mean±SD 0.4±0.9 0.6±0.6 0.1±1.4
# 2 Mean±SD -0.2±0.7 0.6±0.9 1.1±1.4
# 3 Mean±SD -0.1±0.5 0.5±0.6 1.4±0.5
# 4 Mean±SD 2.4±2.3 0.7±1.6 0.2±2.6
# 5 Mean±SD -1.1±1.7 0.7±0.6 1.6±0.9
# 6 Mean±SD -0.9±0.6 0.1±0.3 1.3±0.4
# 7 Mean±SD 0.4±0.8 1.0±0.4 1.6±0.6
# 8 Mean±SD 2.6±1.2 0.2±0.7 0.9±0.9
# 9 Mean±SD -0.7±0.8 0.3±0.6 0.4±0.5
# 10 Mean±SD -1.8±2.1 -0.1±2.2 1.1±1.6
# 11 Mean±SD 0.3±1.8 -0.1±0.6 1.2±0.4
# 12 Mean±SD -0.0±1.1 0.7±0.8 1.6±0.7
# 13 Mean±SD -2.9±2.3 -0.2±1.5 1.1±0.9
# 14 Mean±SD 0.2±1.1 0.6±0.9 0.8±0.3
# 15 Mean±SD -0.4±1.3 0.8±0.8 1.6±1.3
# 16 Mean±SD -0.1±0.5 0.7±1.1 1.2±0.6
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Table 4a. For both patient groups, the dosimetric differences for the bowel cavity between prone and 
supine position for matching primary/nodal margin combination.
bowel cavity Dmean (Gy) bowel cavity v15Gy (cm3)
All patients All patients
5/5mm
Mean±SD
P-value
0.7±4.4
0.2
376.2±301.7
<0.001
5/7mm
Mean±SD
P-value
0.7±4.4
0.4
407.7±328.2
<0.001
10/5mm
Mean±SD
P-value
0.7±4.6
0.4
385.0±311.9
<0.001
10/7mm
Mean±SD
P-value
0.8±4.5
0.2
406.3±324.4
<0.001
10/10mm
Mean±SD
P-value
0.8±4.6
0.3
447.6±344.5
<0.001
10/15mm
Mean±SD
P-value
0.8±4.7
0.2
493.0±370.4
<0.001
20/7mm
Mean±SD
P-value
1.2±4.8
0.1
418.3±333.4
<0.001
20/10mm
Mean±SD
P-value
0.9±4.7
0.3
452.4±345.2
<0.001
20/15mm
Mean±SD
P-value
0.8±4.8
0.2
491.1±374.8
<0.001
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Table 4b. For both patient groups, the dosimetric differences (OARs) between prone and supine position 
for matching primary/ nodal margin combination. Positive values indicate that the prone position is in 
favor.
bladder v40Gy(%) Rectum v40Gy(%)
All patients All patients
5/5mm
Mean±SD
P-value
-7.0±11.0
0.003*
10.5±13.2
<0.001
5/7mm
Mean±SD
P-value
-4.5±9.9
0.013*
8.7±14.1
0.004
10/5mm
Mean±SD
P-value
-7.3±10.8
0.001*
12.9±15.7
0.001
10/7mm
Mean±SD
P-value
-4.1±12.5
0.03*
12.4±15.9
0.001
10/10mm
Mean±SD
P-value
-7.3±10.4
0.001*
12.3±16.3
0.001
10/15mm
Mean±SD
P-value
-8.2±10.7
0.001*
11.2±17.1
0.001
20/7mm
Mean±SD
P-value
-10.8±13.5
<0.001*
13.4±16.9
0.002
20/10mm
Mean±SD
P-value
-10.4±12.8
<0.001*
14.7±16.0
<0.001
20/15mm
Mean±SD
P-value
-10.5±12.0
<0.001*
13.2±14.6
<0.001
*Supine position in favor
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Figure	  5a.	  Response	  rate	  by	  week.	  Patients	  either	  missed	  the	  assessment,	  stopped	  participating,	  had	  
progressive	  disease	  or	  the	  follow-­‐up	  at	  the	  time	  of	  evaluation	  was	  not	  yet	  reached.	  
	  
	  
	  
	  
	  
	   	  
Figure 5a. Response rate by week. Patients either missed the assessment, stopped participating, had pro-
gressive disease or the follow-up at the time of evaluation was not yet reached.
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Figure 5b. This figure represents for each single-item symptom the distribution of the response rates in 
percentages. (continued)
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Figure 5b. This figure represents for each single-item symptom the distribution of the response rates in 
percentages. (continued)
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Figure 5b. This figure represents for each single-item symptom the distribution of the response rates in 
percentages. (continued)
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Figure 5b. This figure represents for each single-item symptom the distribution of the response rates in 
percentages. (continued)
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Figure 5b. This figure represents for each single-item symptom the distribution of the response rates in 
percentages. (continued)
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Table 5c. Influence of different patient and treatment characteristics on the outcome of the most reported 
single item symptoms diarrhea and dysuria.
Diarrhea (5th week)* Dysuria (5th week)#
P-value P-value
nodal boost
yes/no 0.74 0.53
Motion
Mover vs non-mover 0.27 0.75
Treatment
CT+RT, nACT+RT+HT
RT+HT
RT
0.12 0.14
Ln
PAo 0.10 0.38
Treatment position
Prone vs supine 0.28 0.16
Selection backup plan
 (>5) 0.17 0.64
volume
PTv 0.79 (R=0.16) 0.57 (R=0.24)
*Mean 49.2±29.4 (n=111)
#Mean 50.3±35.2 (n=110)
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Figure 6a. Box plot of the cervix-uterus V95 for each patient. The boxes are the first and third quartiles, with 
median as the horizontal line inside the box. Upper and lower limits are the 95 and 5 percentiles.
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Summary 
SuMMARy 
The focus of this thesis lies on describing, evaluating and improving an online, adaptive 
Plan-of-the-Day approach (PotD) in EBRT for locally advanced cervical cancer patients.
Chapter 1 contains a general introduction into cervical cancer and the use of online 
adaptive radiotherapy in locally advanced cervical cancer treatment. It concludes with a 
brief overview of the research described in the thesis.
In Chapter 2 we evaluated the clinical implementation of the online PotD protocol for 
treatment of locally advanced cervical cancer, to cope with patient-specific, non-rigid 
target motion. Based on the first 64 patients, it was concluded that the PotD approach 
was feasible with limited extra treatment time. Two phases of clinical implementation 
were investigated. In the first phase, the plan library contained one IMRT plan for each 
patient based on a personalized ITV, and a motion robust 3DCRT backup plan. This first 
phase was beneficial for patients with < 2.5 cm tip of uterus motion (‘non-movers’; 
assessed from full and empty bladder planning CT scans). For patients with > 2.5 cm 
motion (‘movers’), the advantage of IMRT was lost because of the large margins that 
were needed. In the second phase, movers had two IMRT plans in the plan library, one 
for relatively filled bladders, and the other for relatively empty bladders. For non-movers 
still had one IMRT plan. Compared to the motion robust backup plan, movers with two 
IMRT plans showed a reduction of 26-29% in volume of small bowel cavity receiving 
>99% of the prescription dose.
Chapter 3 describes the quantification of intra-fraction cervix-uterus motion, using 
pre- and post-fraction CBCT scans of 16 movers. A correlation was found between the 
bladder inflow rate and the intra-fraction motion. Considerable intra-fraction cervix-
uterus motion was observed, requiring appropriate PTV margins (5 mm margin for the 
AP direction, covering 90% of the patients). For all patient included in the study, the 
applied CTV-to-PTV margins were sufficient. Since the introduction of VMAT, the treat-
ment time has reduced from 11 minutes to 4.8 minutes. Most probably, this reduces the 
extent of intra-fraction motion for most patients.
Chapter 4 reports on the value of treatment in prone position compared to supine. 
At the time of the study, patients were routinely treated prone in a bellyboard, based on 
a previously observed advantage for small bowel. However, this was based on 3DCRT/ 
IMRT and the use of large margins. The question was whether the advantages would 
still be true would still remain in modern adaptive radiotherapy using smaller margins. 
In collaboration with the Academic Medical Center, Amsterdam, a treatment planning 
study was performed for 26 patients. Using 9 different CTV-to-PTV margins we dem-
onstrated that with small margins and a modern delivery technique (VMAT), the prone 
position has no significant advantage compared to the supine position; there was no 
preference for a prone or supine setup in terms of small bowel sparing for PTV margins 
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(<10mm). The recommendation of this study was to treat all gynecological cancer pa-
tients with image guided radiotherapy in supine position. However, when large margins 
are needed, the prone position still has a significant advantage over the supine position.
Chapter 5 discusses prospective assessments of Quality of Life and toxicity symptoms 
in the acute treatment phase until one year after treatment with a focus on the first three 
months. Most symptoms had the highest incidence at the end of treatment with return 
to baseline values at three months. Several symptoms, including diarrhea, dysuria, bowel 
cramps and sexual problems, became apparent during treatment and persisted thereaf-
ter. Probably, the end of external beam treatment is a suitable time point for assessment 
of future improvements in adaptive therapy regarding acute toxicity. Especially baseline 
and the fifth week of treatment could be used to compare observed symptoms with our 
data.
In Chapter 6, the patient-specific, optimal number of library plans in PotD adaptive 
radiotherapy for locally advanced cervical cancer was investigated. Main endpoint was 
OAR dose reduction. Fourteen patients with large cervix-uterus motion (movers) were 
evaluated. For each patient, plan libraries containing 1-4 VMAT plans with individualized 
tight margins were investigated. The plans were generated for ITVs resulting from differ-
ent bladder filling ranges. All study patients showed reduced OAR dose with two tight 
margin plans in the library instead of one, in line with the current treatment protocol. 
Patients with tip of uterus motion >30 mm showed further reduction of bowel dose 
delivery with three plans in the library. Adding a fourth plan could be beneficial for 
patients with extremely large motion (Hausdorff distance ≥50 mm). The overall conclu-
sion was that extending the plan library to more than three tight margin plans was only 
beneficial for a small subgroup of patients. At individual patient level, the Hausdorff 
distance could be used to select patients that would benefit most from adding extra 
plan(s) to the plan library.
Chapter 7 wraps up this thesis with a general discussion related to the main topics 
described and discussion about future research.
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De focus van dit proefschrift ligt op het beschrijven, evalueren en verbeteren van een 
online adaptief ‘Plan-of-the-Day’ protocol bij uitwendige radiotherapie voor patiënten 
met een lokaal uitgebreid cervixcarcinoom (baarmoederhalskanker).
Hoofdstuk 1 bevat een algemene inleiding over cervixcarcinoom en het gebruik 
van een online adaptieve bestralingstechniek in de behandeling van lokaal uitgebreid 
cervixcarcinoom. Aan het einde volgt een kort overzicht over het onderzoek zoals dat 
beschreven is in dit proefschrift.
In hoofdstuk 2 onderzochten we de klinische implementatie van het online adaptieve 
‘Plan-of-the-Day’ protocol voor de behandeling van lokaal uitgebreid cervixcarcinoom 
en om te gaan met de patiënt-specifieke, niet-rigide, baarmoeder beweging. Op basis 
van de eerste 64 patiënten konden we concluderen dat deze online aanpak realiseer-
baar was in een beperkte extra behandeltijd. Twee fases van de klinische implementatie 
werden onderzocht.
In de eerste fase bestond de plan bibliotheek uit één intensiteitgemoduleerde 
radiotherapie (IMRT) plan voor elke patiënt op basis van een gepersonaliseerd intern 
doelvolume (Internal Target Volume, ITV) en een 3D conformeel radiotherapie (3DCRT, 
‘backup plan’) dat rekening houdt met onverwachte beweging van de uterus (baarmoe-
der) en cervix (baarmoederhals). De eerste fase was met name gunstig voor patiënten 
met minder dan 2.5 cm cervix-uterus beweging (zogenoemde ‘non-movers’; beoordeeld 
naar aanleiding van een volle en lege blaas planning CT-scan). Voor patiënten met een 
cervix-uterus beweging van meer dan 2.5 cm (‘movers’), werd het voordeel van de IMRT 
tenietgedaan door de grote marges die nodig waren. In de tweede fase hadden deze 
‘movers’ twee IMRT plannen in de plan bibliotheek, één voor een (nagenoeg) volle blaas 
en het andere voor een (nagenoeg) lege blaas. De ‘non-movers’ hadden nog steeds één 
IMRT plan. Vergeleken met het ‘backup plan’ hadden ‘movers’ met twee IMRT plannen 
een volumereductie van 26 – 29% van de dunne darm dat meer dan 99% van de voor-
geschreven dosis kreeg.
Hoofdstuk 3 beschrijft de kwantificering van intra-fractie baarmoeder beweging 
met behulp van pre- en post fractie ‘cone-beam’ CT (CBCT) scans van 16 ‘movers’. Een 
correlatie werd gevonden tussen de blaasvulling (ml/min) en de intra-fractie beweging 
van de cervix-uterus. Er werd aanzienlijke intra-fractie cervix-uterus beweging waar-
genomen, waarvoor geschikte planning doelvolume (Planning Target Volumes, PTV) 
marges nodig waren (5 mm marge voor de beweging in anterior-posterior (AP) richting, 
geschikt voor 90% van de patiënten). Bij alle patiënten in de studie waren de toegepaste 
klinisch doelvolume (Clinical Target Volume, CTV) naar PTV marges voldoende. Sinds de 
introductie van volumetrisch gemoduleerde rotatietherapie (VMAT) is de behandeltijd 
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sterk verminderd van 11 minuten naar 4,8 minuten. Zeer waarschijnlijk reduceert dit de 
intra-fractie beweging voor de meeste patiënten.
In hoofdstuk 4 is de behandeling in buikligging vergeleken met die in rugligging. 
Op het moment van de studie werden de patiënten routinematig behandeld gebruik-
makend van een zogenaamd ‘bellyboard’, als gevolg van een eerder waargenomen 
voordeel voor de dunne darm. Echter, dit was gebaseerd op 3DCRT/ IMRT en het gebruik 
van grote marges. De vraag was of de voordelen van het ‘bellyboard’ nog steeds stand 
zouden houden in moderne adaptieve radiotherapie technieken met kleinere marges. 
In samenwerking met het Academisch Medisch Centrum, Amsterdam, werd een plan-
ningsstudie uitgevoerd voor 26 patiënten. Negen verschillende CTV naar PTV marges 
werden onderzocht en er werd aangetoond dat wanneer er gebruik gemaakt kan 
worden van kleine marges en een moderne behandeltechniek (VMAT), de buikligging 
geen significant voordeel meer heeft ten opzichte van rugligging. Er was geen signifi-
cant voordeel van buik- of rugligging ten aanzien van dunne darm sparing voor PTV 
marges kleiner dan 10 mm. De aanbeveling uit deze studie was om alle gynaecologische 
kankerpatiënten met beeld-geleide radiotherapie in rugligging te behandelen. Echter, 
wanneer er grote marges nodig zijn heeft de buikligging nog steeds een significant 
voordeel ten opzichte van de rugligging.
Hoofdstuk 5 beschrijft de prospectieve beoordeling van de kwaliteit van leven en 
toxiciteit symptomen in de acute behandelfase tot één jaar na behandeling met een 
focus op de eerste drie maanden. De meeste klachten hadden de hoogste incidentie aan 
het eind van de behandeling met terugkeer naar baseline waardes op 3 maanden. Som-
mige symptomen, met inbegrip van diarree, dysurie, darmkrampen en seksuele proble-
men kwamen aan het licht tijdens de behandeling. Waarschijnlijk is de eindfase van de 
uitwendige bestraling het meest geschikte tijdstip voor de evaluatie van toekomstige 
verbetering van adaptieve radiotherapie technieken wat betreft acute toxiciteit. Vooral 
de resultaten uit de formulieren van de baseline en de vijfde week van de behandeling 
kunnen worden gebruikt om de nieuwe waargenomen symptomen te vergelijken met 
onze gegevens.
In hoofdstuk 6 werd het optimale aantal plannen voor de planbibliotheek in ‘Plan-of-
the-Day’ adaptieve radiotherapie voor lokaal uitgebreid cervixcarcinoom onderzocht. 
Belangrijkste eindpunt van de studie was reductie van de dosis in de kritieke organen. 
Veertien patiënten met een grote cervix-uterus beweging (‘movers’) werden geëvalu-
eerd. Voor elke patiënt werd een plan bibliotheek, 1-4 VMAT plannen bevattend, met 
geïndividualiseerde krappe marges onderzocht. De plannen werden gegenereerd voor 
ITVs van verschillende blaasvolumes. Bij alle patiënten uit de studie namen we vermin-
derde dosis van de kritieke organen waar bij het toevoegen van twee krappe marge 
plannen ten opzichte van één plan met individuele marges aan de planbibliotheek, in 
lijn met het huidige behandelprotocol. Patiënten met een cervix-uterus beweging van 
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meer dan 30 mm hadden een verder gereduceerde darmdosis bij het toevoegen van 
drie plannen in de planbibliotheek. Het toevoegen van een vierde plan zou gunstig zijn 
voor patiënten met extreme cervix-uterus beweging (‘Hausdorff distance’ ≥50 mm). De 
algemene conclusie was dat de uitbreiding van de planbibliotheek met meer dan drie 
krappe marge plannen alleen gunstig was voor een kleine subgroep van patiënten. Op 
individueel patiëntniveau kan de ‘Hausdorff distance’ gebruikt worden om patiënten 
te selecteren die het meeste voordeel zouden hebben van het toevoegen van extra 
plan(nen) aan de planbibliotheek.
Hoofdstuk 7 sluit deze thesis af met een algemene discussie die betrekking heeft op 
de belangrijkste onderwerpen uit dit proefschrift en bevat tevens een discussie over 
toekomstige onderzoeksmogelijkheden.
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